Roxana Mehran

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/12000642/publications.pdf

Version: 2024-02-01

634 papers	84,717 citations	640 123 h-index	418 276 g-index
645 all docs	645 docs citations	645 times ranked	38913 citing authors

#	Article	IF	Citations
1	Clinical End Points in Coronary Stent Trials. Circulation, 2007, 115, 2344-2351.	1.6	4,993
2	Standardized Bleeding Definitions for Cardiovascular Clinical Trials. Circulation, 2011, 123, 2736-2747.	1.6	3,378
3	A Prospective Natural-History Study of Coronary Atherosclerosis. New England Journal of Medicine, 2011, 364, 226-235.	13.9	2,721
4	From Vulnerable Plaque to Vulnerable Patient. Circulation, 2003, 108, 1664-1672.	1.6	2,308
5	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2011, 58, e44-e122.	1.2	2,027
6	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Circulation, 2011, 124, e574-651.	1.6	1,946
7	Safety and Efficacy of Sirolimus- and Paclitaxel-Eluting Coronary Stents. New England Journal of Medicine, 2007, 356, 998-1008.	13.9	1,776
8	Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. New England Journal of Medicine, 2017, 377, 111-121.	13.9	1,738
9	Bivalirudin during Primary PCI in Acute Myocardial Infarction. New England Journal of Medicine, 2008, 358, 2218-2230.	13.9	1,693
10	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). European Journal of Cardio-thoracic Surgery, 2012, 42, S45-S60.	0.6	1,605
11	From Vulnerable Plaque to Vulnerable Patient. Circulation, 2003, 108, 1772-1778.	1.6	1,562
12	Updated Standardized Endpoint Definitions for Transcatheter Aortic Valve Implantation. Journal of the American College of Cardiology, 2012, 60, 1438-1454.	1.2	1,560
13	Bivalirudin for Patients with Acute Coronary Syndromes. New England Journal of Medicine, 2006, 355, 2203-2216.	13.9	1,367
14	Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. New England Journal of Medicine, 2016, 375, 2423-2434.	13.9	1,265
15	2016 ACC/AHA Guideline FocusedÂUpdate on Duration of DualÂAntiplatelet Therapy in Patients With Coronary Artery Disease. Journal of the American College of Cardiology, 2016, 68, 1082-1115.	1.2	1,232
16	Angiographic Patterns of In-Stent Restenosis. Circulation, 1999, 100, 1872-1878.	1.6	1,151
17	Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. New England Journal of Medicine, 2016, 375, 2349-2358.	13.9	979
18	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus documentâ€. European Heart Journal, 2012, 33, 2403-2418.	1.0	900

#	Article	IF	Citations
19	Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. New England Journal of Medicine, 2016, 375, 2223-2235.	13.9	843
20	Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. New England Journal of Medicine, 2019, 380, 1509-1524.	13.9	833
21	Safety and Efficacy of Drug-Eluting and Bare Metal Stents. Circulation, 2009, 119, 3198-3206.	1.6	794
22	Updated standardized endpoint definitions for transcatheter aortic valve implantation: The Valve Academic Research Consortium-2 consensus document. Journal of Thoracic and Cardiovascular Surgery, 2013, 145, 6-23.	0.4	783
23	Impact of Major Bleeding on 30-Day Mortality and Clinical Outcomes in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2007, 49, 1362-1368.	1.2	776
24	Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet, The, 2013, 382, 614-623.	6.3	740
25	Standardized Endpoint Definitions for Transcatheter Aortic Valve Implantation Clinical Trials. Journal of the American College of Cardiology, 2011, 57, 253-269.	1.2	735
26	Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. European Heart Journal, 2011, 32, 205-217.	1.0	719
27	2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2016, 67, 1235-1250.	1.2	684
28	Ticagrelor with or without Aspirin in High-Risk Patients after PCI. New England Journal of Medicine, 2019, 381, 2032-2042.	13.9	683
29	The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. Journal of the American College of Cardiology, 2000, 36, 1542-1548.	1.2	669
30	In-Stent Restenosis in the Drug-Eluting Stent Era. Journal of the American College of Cardiology, 2010, 56, 1897-1907.	1.2	663
31	Paclitaxel-Eluting Stents versus Bare-Metal Stents in Acute Myocardial Infarction. New England Journal of Medicine, 2009, 360, 1946-1959.	13.9	657
32	A Risk Score to Predict Bleeding in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2010, 55, 2556-2566.	1.2	590
33	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. Journal of the American College of Cardiology, 2022, 79, e21-e129.	1.2	561
34	Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet, The, 2013, 382, 1714-1722.	6.3	537
35	Consideration of a New Definition of Clinically Relevant Myocardial Infarction AfterÂCoronary Revascularization. Journal of the American College of Cardiology, 2013, 62, 1563-1570.	1.2	506
36	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary. Circulation, 2011, 124, 2574-2609.	1.6	500

#	Article	IF	Citations
37	Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction. JAMA - Journal of the American Medical Association, 2012, 307, 1817.	3.8	471
38	Exome-wide association study of plasma lipids in >300,000 individuals. Nature Genetics, 2017, 49, 1758-1766.	9.4	470
39	Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents. Journal of the American College of Cardiology, 2016, 67, 2224-2234.	1.2	445
40	Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. Circulation, 2018, 137, 2635-2650.	1.6	435
41	2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials. Journal of the American College of Cardiology, 2015, 66, 403-469.	1.2	428
42	Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Circulation, 2019, 140, 240-261.	1.6	428
43	Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet, The, 2011, 377, 2193-2204.	6.3	421
44	Valve Academic Research Consortium 3: Updated Endpoint Definitions for AorticÂValve Clinical Research. Journal of the American College of Cardiology, 2021, 77, 2717-2746.	1.2	416
45	The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. Journal of the American College of Cardiology, 1998, 32, 584-589.	1.2	415
46	Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: PartÂ2: Endpoint Definitions. Journal of the American College of Cardiology, 2015, 66, 308-321.	1.2	413
47	Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. European Heart Journal, 2007, 28, 1709-1716.	1.0	411
48	Prevalence, Impact, and Predictive Value ofÂDetecting Subclinical Coronary and CarotidÂAtherosclerosis in Asymptomatic Adults. Journal of the American College of Cardiology, 2015, 65, 1065-1074.	1.2	379
49	Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet, The, 2009, 374, 1149-1159.	6.3	368
50	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. Circulation, 2018, 137, 961-972.	1.6	368
51	Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet, The, 2007, 369, 907-919.	6.3	367
52	Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary proceduresA meta-analysis. Journal of the American College of Cardiology, 2004, 44, 1200-1209.	1.2	366
53	Percutaneous Recanalization of Chronically Occluded Coronary Arteries. Circulation, 2005, 112, 2530-2537.	1.6	365
54	2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials. Circulation, 2015, 132, 302-361.	1.6	364

#	Article	IF	Citations
55	A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. New England Journal of Medicine, 2020, 382, 120-129.	13.9	362
56	Relationship Between Intravascular Ultrasound Guidance and Clinical Outcomes After Drug-Eluting Stents. Circulation, 2014, 129, 463-470.	1.6	350
57	Incidence, Predictors, and Impact ofÂPost-Discharge Bleeding After Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2015, 66, 1036-1045.	1.2	344
58	Ischemic Outcomes After Coronary Intervention of Calcified Vessels in Acute Coronary Syndromes. Journal of the American College of Cardiology, 2014, 63, 1845-1854.	1.2	343
59	Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. European Heart Journal, 2021, 42, 1825-1857.	1.0	342
60	Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. European Heart Journal, 2019, 40, 2632-2653.	1.0	335
61	Impact of Bleeding on Mortality After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2011, 4, 654-664.	1.1	329
62	Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. European Heart Journal, 2009, 30, 1457-1466.	1.0	315
63	Duration of Dual Antiplatelet Therapy AfterÂDrug-Eluting Stent Implantation. Journal of the American College of Cardiology, 2015, 65, 1298-1310.	1.2	314
64	Quantification and Impact of Untreated Coronary Artery Disease After Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2012, 59, 2165-2174.	1.2	310
65	Intracoronary Î²-Radiation Therapy Inhibits Recurrence of In-Stent Restenosis. Circulation, 2000, 101, 1895-1898.	1.6	304
66	International Expert Consensus on Switching Platelet P2Y ₁₂ Receptorâ€“Inhibiting Therapies. Circulation, 2017, 136, 1955-1975.	1.6	293
67	2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. Journal of the American College of Cardiology, 2017, 70, 3042-3067.	1.2	285
68	Evaluation and Treatment of Patients With Lower Extremity Peripheral ArteryÂDisease. Journal of the American College of Cardiology, 2015, 65, 931-941.	1.2	269
69	Routine Upstream Initiation vs Deferred Selective Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2007, 297, 591.	3.8	266
70	Contribution of Stent Underexpansion to Recurrence After Sirolimus-Eluting Stent Implantation for In-Stent Restenosis. Circulation, 2004, 109, 1085-1088.	1.6	263
71	Long-Term Outcome of Percutaneous Coronary Intervention for Chronic Total Occlusions. JACC: Cardiovascular Interventions, 2011, 4, 952-961.	1.1	260
72	Impact of the Everolimus-Eluting Stent on Stent Thrombosis. Journal of the American College of Cardiology, 2011, 58, 1569-1577.	1.2	258

#	Article	IF	Citations
73	Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. EuroIntervention, 2010, 5, 871-874.	1.4	257
74	Atherosclerotic Plaque Burden and CK-MB Enzyme Elevation After Coronary Interventions. Circulation, 2000, 101, 604-610.	1.6	256
75	Prognostic Impact of Staged Versus â€œOne-Timeâ€•Multivessel Percutaneous Intervention in Acute Myocardial Infarction. Journal of the American College of Cardiology, 2011, 58, 704-711.	1.2	236
76	Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: Study design and rationale. American Heart Journal, 2004, 148, 764-775.	1.2	231
77	Incidence, Prognostic Impact, and Influence of Antithrombotic Therapy on Access and Nonaccess Site Bleeding in Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2011, 4, 191-197.	1.1	229
78	Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. European Heart Journal, 2007, 28, 1936-1945.	1.0	223
79	A Registry-Based Randomized Trial Comparing Radial and Femoral Approaches in Women Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2014, 7, 857-867.	1.1	223
80	Frequency and Predictors of Stent Thrombosis After Percutaneous Coronary Intervention in Acute Myocardial Infarction. Circulation, 2011, 123, 1745-1756.	1.6	222
81	Creatine Kinase-MB Enzyme Elevation Following Successful Saphenous Vein Graft Intervention Is Associated With Late Mortality. Circulation, 1999, 100, 2400-2405.	1.6	217
82	Antithrombotic Strategies in Patients With Acute Coronary Syndromes Undergoing Early Invasive Management. JAMA - Journal of the American Medical Association, 2007, 298, 2497.	3.8	217
83	Changes in Plaque Lipid Content After Short-Term Intensive Versus Standard StatinÂTherapy. Journal of the American College of Cardiology, 2013, 62, 21-29.	1.2	217
84	Late total occlusion after intracoronary brachytherapy for patients with in-stent restenosis. Journal of the American College of Cardiology, 2000, 36, 65-68.	1.2	216
85	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. Journal of the American College of Cardiology, 2018, 71, 1021-1034.	1.2	211
86	Contrast-induced acute kidney injury after primary percutaneous coronary intervention: results from the HORIZONS-AMI substudy. European Heart Journal, 2014, 35, 1533-1540.	1.0	210
87	Differential Impact on Survival of Electrocardiographic Q-Wave Versus Enzymatic Myocardial Infarction After Percutaneous Intervention. Circulation, 2001, 104, 642-647.	1.6	207
88	Prognostic impact of a chronic total occlusion in a non-infarct-related artery in patients with ST-segment elevation myocardial infarction: 3-year results from the HORIZONS-AMI trial. European Heart Journal, 2012, 33, 768-775.	1.0	206
89	Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. JAMA Cardiology, 2019, 4, 747.	3.0	198
90	Intravascular Ultrasound Findings of Early Stent Thrombosis After Primary Percutaneous Intervention in Acute Myocardial Infarction. Circulation: Cardiovascular Interventions, 2011, 4, 239-247.	1.4	196

#	Article	IF	Citations
91	2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. Journal of the American College of Cardiology, 2020, 76, 594-622.	1.2	187
92	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document#. EuroIntervention, 2012, 8, 782-795.	1.4	182
93	Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. Nature Reviews Cardiology, 2018, 15, 480-496.	6.1	180
94	Standardized End Point Definitions for Coronary Intervention Trials. European Heart Journal, 2018, 39, 2192-2207.	1.0	179
95	ST-segment elevation myocardial infarction. Nature Reviews Disease Primers, 2019, 5, 39.	18.1	179
96	Prognostic Significance of Periprocedural Versus Spontaneously Occurring Myocardial Infarction After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2009, 54, 477-486.	1.2	178
97	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, 145, CIR0000000000001038.	1.6	177
98	Early Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Drug-Eluting and Bare Metal Stents. Circulation, 2009, 119, 687-698.	1.6	172
99	One-year follow-up after intravascular ultrasound assessment of moderate left main coronary artery disease in patients with ambiguous angiograms. Journal of the American College of Cardiology, 1999, 34, 707-715.	1.2	171
100	Gastrointestinal Bleeding in Patients With Acute Coronary Syndromes: Incidence, Predictors, and Clinical Implications. Journal of the American College of Cardiology, 2009, 54, 1293-1302.	1.2	170
101	Stent Thrombosis. JACC: Cardiovascular Interventions, 2014, 7, 1081-1092.	1.1	159
102	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary. Catheterization and Cardiovascular Interventions, 2012, 79, 453-495.	0.7	157
103	Strut Coverage and Late Malapposition With Paclitaxel-Eluting Stents Compared With Bare Metal Stents in Acute Myocardial Infarction. Circulation, 2011, 123, 274-281.	1.6	155
104	The Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: Study design and rationale. American Heart Journal, 2008, 156, 44-56.	1.2	152
105	Stable coronary artery disease: revascularisation and invasive strategies. Lancet, The, 2015, 386, 702-713.	6.3	152
106	Antithrombotic Treatment in Transcatheter Aortic Valve Implantation. Journal of the American College of Cardiology, 2013, 62, 2349-2359.	1.2	151
107	Prognosis of Patients With Nonâ€“ST-Segmentâ€“Elevation Myocardial Infarction and Nonobstructive Coronary Artery Disease. Circulation: Cardiovascular Interventions, 2014, 7, 285-293.	1.4	151
108	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary. Journal of the American College of Cardiology, 2022, 79, 197-215.	1.2	150

#	Article	IF	Citations
109	Impact of Contrast-Induced Acute Kidney Injury After Percutaneous Coronary Intervention on Short- and Long-Term Outcomes. Circulation: Cardiovascular Interventions, 2015, 8, e002475.	1.4	148
110	Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction. Circulation, 2016, 134, 1918-1930.	1.6	148
111	Role of Clopidogrel Loading Dose in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Angioplasty. Journal of the American College of Cardiology, 2009, 54, 1438-1446.	1.2	147
112	Sodium Bicarbonate for the Prevention of Contrast Induced-Acute Kidney Injury. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1584-1592.	2.2	146
113	2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease. Journal of the American College of Cardiology, 2021, 77, 629-658.	1.2	144
114	P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. BMJ, The, 2021, 373, n1332.	3.0	144
115	5-Year Clinical Outcomes After Sirolimus-Eluting Stent Implantation. Journal of the American College of Cardiology, 2009, 54, 894-902.	1.2	142
116	Treatment of In-Stent Restenosis With Excimer Laser Coronary Angioplasty Versus Rotational Atherectomy. Circulation, 2000, 101, 2484-2489.	1.6	140
117	Outcomes Following Pre-Operative Clopidogrel Administration in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery. Journal of the American College of Cardiology, 2009, 53, 1965-1972.	1.2	140
118	An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). American Heart Journal, 2015, 169, 472-478.e5.	1.2	140
119	Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients. Journal of the American College of Cardiology, 2020, 75, 2711-2722.	1.2	139
120	Impact of Routine Angiographic Follow-Up on the Clinical Benefits of Paclitaxel-Eluting Stents. Journal of the American College of Cardiology, 2006, 48, 32-36.	1.2	134
121	Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitions. European Heart Journal, 2015, 36, 1878-1891.	1.0	133
122	Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations. Circulation, 2021, 143, 479-500.	1.6	132
123	Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. Lancet, The, 2013, 382, 1879-1888.	6.3	127
124	Management of Antithrombotic Therapy in Atrial Fibrillation Patients UndergoingÂPCI. Journal of the American College of Cardiology, 2019, 74, 83-99.	1.2	126
125	Impact of the Presence and Extent of Incomplete Angiographic Revascularization After Percutaneous Coronary Intervention in Acute Coronary Syndromes. Circulation, 2012, 125, 2613-2620.	1.6	125
126	Ticagrelor With or Without Aspirin After ComplexÂPCI. Journal of the American College of Cardiology, 2020, 75, 2414-2424.	1.2	122

#	Article	IF	Citations
127	Drug-Eluting Stent for Left Main Coronary Artery Disease. JACC: Cardiovascular Interventions, 2012, 5, 718-727.	1.1	121
128	Prognostic Modeling of Individual Patient Risk and Mortality Impact of Ischemic and Hemorrhagic Complications. Circulation, 2010, 121, 43-51.	1.6	120
129	Outcome in Elderly Patients Undergoing Primary Coronary Intervention for Acute Myocardial Infarction. Circulation, 2004, 110, 1598-1604.	1.6	119
130	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. Circulation, 2021, 143, 583-596.	1.6	119
131	Tissue proliferation within and surrounding Palmaz-Schatz stents is dependent on the aggressiveness of stent implantation technique. American Journal of Cardiology, 1999, 83, 1170-1174.	0.7	118
132	Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2015, 66, 2860-2868.	1.2	116
133	Quantitative angiographic methods for appropriate end-point analysis, edge-effect evaluation, and prediction of recurrent restenosis after coronary brachytherapy with gamma irradiation. Journal of the American College of Cardiology, 2002, 39, 274-280.	1.2	115
134	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary. Journal of the American College of Cardiology, 2011, 58, 2550-2583.	1.2	114
135	Sexâ€based differences in bleeding and long term adverse events after percutaneous coronary intervention for acute myocardial infarction: Three year results from the HORIZONSâ€AMI trial. Catheterization and Cardiovascular Interventions, 2015, 85, 359-368.	0.7	112
136	Vasa vasorum imaging: A new window to the clinical detection of vulnerable atherosclerotic plaques. Current Atherosclerosis Reports, 2005, 7, 164-169.	2.0	110
137	A Novel Bioresorbable Polymer Paclitaxel-Eluting Stent for the Treatment of Single and Multivessel Coronary Disease. Journal of the American College of Cardiology, 2008, 51, 1543-1552.	1.2	109
138	Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. Lancet, The, 2016, 387, 349-356.	6.3	109
139	Choice of arterial access site and outcomes in patients with acute coronary syndromes managed with an early invasive strategy: the ACUITY trial. EuroIntervention, 2009, 5, 115-120.	1.4	109
140	Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. American Heart Journal, 2016, 182, 125-134.	1.2	108
141	Long-Term Impact of Chronic Kidney Disease in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2011, 4, 1011-1019.	1.1	107
142	Paclitaxel-Eluting Coronary Stents in Patients With Diabetes Mellitus. Journal of the American College of Cardiology, 2008, 51, 708-715.	1.2	106
143	Impact of Intravascular Ultrasound Imaging on Early and Late Clinical Outcomes Following Percutaneous Coronary Intervention With Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2011, 4, 974-981.	1.1	106
144	Duration of Dual Antiplatelet Therapy AfterÂCoronary Stenting. Journal of the American College of Cardiology, 2015, 66, 832-847.	1.2	105

#	Article	IF	Citations
145	Randomized trial of Rotational Atherectomy Versus Balloon Angioplasty for Diffuse In-stent Restenosis (ROSTER). American Heart Journal, 2004, 147, 16-22.	1.2	101
146	Impact of Delay to Angioplasty in Patients With Acute Coronary Syndromes Undergoing Invasive Management. Journal of the American College of Cardiology, 2010, 55, 1416-1424.	1.2	101
147	When Is Door-to-Balloon Time Critical?. Journal of the American College of Cardiology, 2010, 56, 407-413.	1.2	101
148	Development and Validation of a Stent Thrombosis Risk Score in Patients With Acute Coronary Syndromes. JACC: Cardiovascular Interventions, 2012, 5, 1097-1105.	1.1	101
149	Gender-Specific Outcomes After Sirolimus-Eluting Stent Implantation. Journal of the American College of Cardiology, 2007, 50, 2111-2116.	1.2	97
150	9-Month Clinical, Angiographic, and Intravascular Ultrasound Results of a Prospective Evaluation of the Axxess Self-Expanding Biolimus A9-Eluting Stent in Coronary Bifurcation Lesions. Journal of the American College of Cardiology, 2009, 53, 1031-1039.	1.2	97
151	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2013, 82, E266-355.	0.7	97
152	Intravascular ultrasound assessment of lesions with target vessel failure after sirolimus-eluting stent implantation. American Journal of Cardiology, 2005, 95, 498-502.	0.7	95
153	The REMEDEE Trial. JACC: Cardiovascular Interventions, 2013, 6, 334-343.	1.1	95
154	Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study. American Heart Journal, 2017, 184, 81-87.	1.2	95
155	Impact of Femoral Vascular Closure Devices and Antithrombotic Therapy on Access Site Bleeding in Acute Coronary Syndromes. Circulation: Cardiovascular Interventions, 2010, 3, 57-62.	1.4	94
156	Coronary Plaque Composition, Morphology, and Outcomes in Patients With and Without Chronic Kidney Disease Presenting With Acute Coronary Syndromes. JACC: Cardiovascular Imaging, 2012, 5, S53-S61.	2.3	93
157	Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. European Heart Journal, 2014, 35, 2285-2294.	1.0	93
158	Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. European Heart Journal, 2020, 41, 3533-3545.	1.0	93
159	Incidence and angiographic characteristics of patients With apical ballooning syndrome (takotsubo/stress cardiomyopathy) in the HORIZONSâ€AMI trial. Catheterization and Cardiovascular Interventions, 2014, 83, 343-348.	0.7	92
160	Incidence and predictors of heart failure following percutaneous coronary intervention in ST-segment elevation myocardial infarction: The HORIZONS-AMI trial. American Heart Journal, 2011, 162, 663-670.	1.2	87
161	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. Nature Reviews Cardiology, 2020, 17, 242-257.	6.1	87
162	Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: Results from the TAXUS-IV Trial. American Heart Journal, 2005, 150, 1163-1170.	1.2	86

#	Article	IF	Citations
163	A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. European Heart Journal, 2013, 34, 2481-2489.	1.0	85
164	Impact of Coronary Lesion Complexity on Drug-Eluting Stent Outcomes in Patients With and Without Diabetes Mellitus. Journal of the American College of Cardiology, 2014, 63, 2111-2118.	1.2	85
165	Acute and 30-Day Outcomes in WomenÂAfter TAVR. JACC: Cardiovascular Interventions, 2016, 9, 1589-1600.	1.1	85
166	Nonrandomized Comparison of Coronary Stenting Under Intravascular Ultrasound Guidance of Direct Stenting Without Predilation Versus Conventional Predilation With a Semi-Compliant Balloon Versus Predilation With a New Scoring Balloon. American Journal of Cardiology, 2007, 100, 812-817.	0.7	84
167	Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention. Circulation, 2020, 141, 1618-1627.	1.6	84
168	Assessing intermediate left main coronary lesions using intravascular ultrasound. American Heart Journal, 2007, 154, 983-988.	1.2	83
169	Selection Criteria for Drug-Eluting Versus Bare-Metal Stents and the Impact of Routine Angiographic Follow-Up. Journal of the American College of Cardiology, 2010, 56, 1597-1604.	1.2	83
170	Impact of Gender and Antithrombin Strategy on Early and Late Clinical Outcomes in Patients With Nonâ€“ST-Elevation Acute Coronary Syndromes (from the ACUITY Trial). American Journal of Cardiology, 2009, 103, 1196-1203.	0.7	81
171	Impact of Anemia on Clinical Outcomes of Patients With ST-Segment Elevation Myocardial Infarction in Relation to Gender and Adjunctive Antithrombotic Therapy (from the HORIZONS-AMI Trial). American Journal of Cardiology, 2010, 105, 1385-1394.	0.7	80
172	Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. Circulation, 2020, 141, 781-783.	1.6	80
173	Early Lumen Loss After Treatment of In-Stent Restenosis. Circulation, 1998, 98, 200-203.	1.6	77
174	Impact of hyperglycemia in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: The HORIZONS-AMI trial. International Journal of Cardiology, 2013, 167, 2572-2579.	0.8	77
175	Rate of peri-procedural stroke observed with cerebral embolic protection during transcatheter aortic valve replacement: a patient-level propensity-matched analysis. European Heart Journal, 2019, 40, 1334-1340.	1.0	77
176	Coronary Calcification and Long-TermÂOutcomes According to Drug-Eluting Stent Generation. JACC: Cardiovascular Interventions, 2020, 13, 1417-1428.	1.1	77
177	Long-Term Clinical Outcomes After Percutaneous Coronary Intervention for Ostial/Mid-Shaft Lesions Versus Distal Bifurcation Lesions in Unprotected LeftÂMain Coronary Artery. JACC: Cardiovascular Interventions, 2013, 6, 1242-1249.	1.1	75
178	The prognostic importance of left ventricular function in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. European Heart Journal: Acute Cardiovascular Care, 2014, 3, 67-77.	0.4	75
179	Impact of Atrial Fibrillation in Patients With ST-Elevation Myocardial Infarction Treated With Percutaneous Coronary Intervention (from the HORIZONS-AMI [Harmonizing Outcomes With) Tj ETQq1 1 0.784314 rgBT /Overlock 10 2014, 113, 236-242.	0.7	75
180	Safety and Efficacy of Switching From Either Unfractionated Heparin or Enoxaparin to Bivalirudin in Patients With Nonâ€“ST-Segment Elevation Acute Coronary Syndromes Managed With an Invasive Strategy. Journal of the American College of Cardiology, 2008, 51, 1734-1741.	1.2	74

#	Article	IF	Citations
181	Safety and Efficacy of Bivalirudin With and Without Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2008, 52, 807-814.	1.2	72
182	Economic Evaluation of Bivalirudin With or Without Glycoprotein IIb/IIIa Inhibition Versus Heparin With Routine Glycoprotein IIb/IIIa Inhibition for Early Invasive Management of Acute Coronary Syndromes. Journal of the American College of Cardiology, 2008, 52, 1758-1768.	1.2	72
183	Coronary In-Stent Restenosis. Journal of the American College of Cardiology, 2022, 80, 348-372.	1.2	72
184	Impact of major bleeding and blood transfusions after cardiac surgery: Analysis from the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial. American Heart Journal, 2012, 163, 522-529.	1.2	71
185	Embedding a randomized clinical trial into an ongoing registry infrastructure: Unique opportunities for efficiency in design of the Study of Access site For Enhancement of Percutaneous Coronary Intervention for Women (SAFE-PCI for Women). American Heart Journal, 2013, 166, 421-428.e1.	1.2	71
186	Long-Term Prognosis of Patients Presenting With ST-Segment Elevation Myocardial Infarction With No Significant Coronary Artery Disease (from The HORIZONS-AMI Trial). American Journal of Cardiology, 2013, 111, 643-648.	0.7	71
187	Two-year outcomes after percutaneous coronary intervention of calcified lesions with drug-eluting stents. International Journal of Cardiology, 2017, 231, 61-67.	0.8	71
188	Sex Differences in Transfemoral Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2019, 74, 2758-2767.	1.2	71
189	Predictors, Incidence, and Outcomes of Patients Undergoing Transfemoral Transcatheter Aortic Valve Implantation Complicated by Stroke. Circulation: Cardiovascular Interventions, 2019, 12, e007546.	1.4	71
190	Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. JAMA Cardiology, 2020, 5, 582.	3.0	71
191	Bleeding avoidance strategies in percutaneous coronary intervention. Nature Reviews Cardiology, 2022, 19, 117-132.	6.1	71
192	New approaches to preventing restenosis. BMJ: British Medical Journal, 2003, 327, 274-279.	2.4	69
193	Prognostic Impact of Blood Transfusion After Primary Angioplasty for Acute Myocardial Infarction. JACC: Cardiovascular Interventions, 2009, 2, 624-632.	1.1	69
194	Stroke After Transcatheter Aortic Valve Replacement: Incidence, Risk Factors, Prognosis, and Preventive Strategies. Clinical Cardiology, 2014, 37, 756-764.	0.7	69
195	An open-Label, 2 Ã— 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. American Heart Journal, 2018, 200, 17-23.	1.2	69
196	Residual Inflammatory Risk in PatientsÂWith Low LDL Cholesterol LevelsÂUndergoing Percutaneous CoronaryÂIntervention. Journal of the American College of Cardiology, 2019, 73, 2401-2409.	1.2	69
197	Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal, 2021, 42, 2630-2642.	1.0	69
198	Clinical and Angiographic Predictors of Short- and Long-Term Ischemic Events in Acute Coronary Syndromes. Circulation: Cardiovascular Interventions, 2010, 3, 308-316.	1.4	68

#	Article	IF	Citations
199	Incidence, Predictors, and Implications of Reinfarction After Primary Percutaneous Coronary Intervention in ST-Segmentâ€“Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2014, 7, 543-551.	1.4	67
200	Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions. JACC: Cardiovascular Interventions, 2016, 9, 51-64.	1.1	67
201	Safety and Efficacy of Bivalirudin Monotherapy in Patients With Diabetes Mellitus and Acute Coronary Syndromes. Journal of the American College of Cardiology, 2008, 51, 1645-1652.	1.2	66
202	Impact of Chronic Kidney Disease on Early (30-Day) and Late (1-Year) Outcomes of Patients With Acute Coronary Syndromes Treated With Alternative Antithrombotic Treatment Strategies. JACC: Cardiovascular Interventions, 2009, 2, 748-757.	1.1	66
203	Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary PCI: An updated meta-analysis of 10,350 patients from five randomized clinical trials. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 253-262.	0.4	66
204	Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy. Journal of the American College of Cardiology, 2020, 75, 578-586.	1.2	66
205	Surgical Versus Percutaneous Revascularization for Multivessel Disease in Patients With Acute Coronary Syndromes. JACC: Cardiovascular Interventions, 2010, 3, 1059-1067.	1.1	65
206	Prevalence and Impact of High Platelet Reactivity in Chronic Kidney Disease. Circulation: Cardiovascular Interventions, 2015, 8, e001683.	1.4	65
207	Reduction in Cardiac Mortality With Bivalirudin in Patients With and Without Major Bleeding. Journal of the American College of Cardiology, 2014, 63, 15-20.	1.2	64
208	Validation of the in vivo intravascular ultrasound measurement of in-stent neointimal hyperplasia volumes. Journal of the American College of Cardiology, 1998, 32, 794-799.	1.2	63
209	Prognostic Significance of Postprocedural Sustained Ventricular Tachycardia or Fibrillation in Patients Undergoing Primary Percutaneous Coronary Intervention (from the HORIZONS-AMI Trial). American Journal of Cardiology, 2012, 109, 805-812.	0.7	63
210	Nonculprit Lesion Plaque Morphology in Patients With ST-Segmentâ€“Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2020, 13, e008768.	1.4	63
211	Impact of Leukocyte Count on Mortality and Bleeding in Patients With Myocardial Infarction Undergoing Primary Percutaneous Coronary Interventions. Circulation, 2011, 123, 2829-2837.	1.6	62
212	Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: An expert consensus document from the society for cardiovascular angiography and interventions (SCAI). Catheterization and Cardiovascular Interventions, 2014, 83, 27-36.	0.7	62
213	Bivalirudin Versus Heparin With or WithoutÂGlycoprotein IIb/IIIa Inhibitors inÂPatients With STEMI Undergoing PrimaryÂPercutaneous Coronary Intervention. Journal of the American College of Cardiology, 2015, 65, 27-38.	1.2	62
214	Short Duration of DAPT Versus De-Escalation After Percutaneous Coronary Intervention for AcuteÂCoronaryÂSyndromes. JACC: Cardiovascular Interventions, 2022, 15, 268-277.	1.1	62
215	Procedural Results and Late Clinical Outcomes After Placement of Three or More Stents in Single Coronary Lesions. Circulation, 1998, 97, 1355-1361.	1.6	61
216	Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2020, 75, 2403-2413.	1.2	60

#	Article	IF	Citations
217	Effectiveness of Drug-Eluting Stent Implantation for Patients With Unprotected Left Main Coronary Artery Stenosis. American Journal of Cardiology, 2008, 101, 801-806.	0.7	59
218	Thrombo-embolic prevention after transcatheter aortic valve implantation. European Heart Journal, 2017, 38, 3341-3350.	1.0	59
219	Influence of Timing of Clopidogrel Treatment on the Efficacy and Safety of Bivalirudin in Patients With Nonâ€“ST-Segment Elevation Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2008, 1, 639-648.	1.1	58
220	Angiographic Patterns of Drug-Eluting Stent Restenosis and One-Year Outcomes After Treatment With Repeated Percutaneous Coronary Intervention. American Journal of Cardiology, 2008, 102, 311-315.	0.7	58
221	Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: Analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. American Heart Journal, 2011, 161, 391-396.	1.2	58
222	Neurological Outcomes With Embolic Protection Devices in Patients Undergoing Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2016, 9, 2124-2133.	1.1	58
223	Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI. Journal of the American College of Cardiology, 2017, 70, 1846-1857.	1.2	58
224	Japan-United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNEichâ€™s Combo StEnt (Japan-USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and drug-eluting stent in patients with ischaemic coronary disease and non-ST-elevation acute coronary syndrome. European Heart Journal, 2018, 39, 2460-2468.	1.0	58
225	Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention. Circulation, 2019, 140, 1921-1932.	1.6	57
226	Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey. European Heart Journal, 2021, 42, 339-351.	1.0	57
227	Impact of Delay to Reperfusion on Reperfusion Success, Infarct Size, and Clinical Outcomes in Patients With ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2014, 7, 733-740.	1.1	56
228	3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation. JACC: Cardiovascular Interventions, 2021, 14, 1870-1883.	1.1	56
229	Complete Revascularization During Primary Percutaneous Coronary Intervention Reduces Death and Myocardial Infarction in Patients With Multivessel Disease. JACC: Cardiovascular Interventions, 2018, 11, 833-843.	1.1	55
230	Antithrombotic Therapy After Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2019, 12, e007411.	1.4	55
231	Outcomes of Patients Treated With Triple Antithrombotic Therapy After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (from the Harmonizing Outcomes With) Tj ETQq1 1 0.784314 rgBT /Overlo of Cardiology, 2012, 109, 831-838.	0.7	54
232	Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2016, 9, 1349-1357.	1.1	54
233	Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. European Heart Journal, 2021, 42, 4624-4634.	1.0	54
234	Short- and Long-Term Outcomes After Stent-Assisted Percutaneous Treatment of Saphenous Vein Grafts in the Drug-Eluting Stent Era. American Journal of Cardiology, 2008, 101, 63-68.	0.7	53

#	Article	IF	Citations
235	Dynamic Nature of Nonculprit Coronary Artery Lesion Morphology in STEMI. JACC: Cardiovascular Imaging, 2013, 6, 86-95.	2.3	53
236	Left Ventricular Thrombus Following Acute Myocardial Infarction. Journal of the American College of Cardiology, 2022, 79, 1010-1022.	1.2	53
237	Safety and Efficacy of Double Antithrombotic Therapy With Nonâ€“Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Metaâ€Analysis. Journal of the American Heart Association, 2020, 9, e017212.	1.6	52
238	Assessing the Risks of Bleeding vs Thrombotic Events in Patients at High Bleeding Risk After Coronary Stent Implantation. JAMA Cardiology, 2021, 6, 410.	3.0	52
239	Volumetric Intravascular Ultrasound Analysis of Paclitaxel-Eluting and Bare Metal Stents in Acute Myocardial Infarction. Circulation, 2009, 120, 1875-1882.	1.6	51
240	Clinical Outcomes Following Stent Thrombosis Occurring In-Hospital Versus Out-of-Hospital. Journal of the American College of Cardiology, 2012, 59, 1752-1759.	1.2	51
241	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization. JACC: Cardiovascular Interventions, 2016, 9, 674-684.	1.1	51
242	Effect of Baseline Thrombocytopenia on Ischemic Outcomes in Patients With Acute Coronary Syndromes Who Undergo Percutaneous Coronary Intervention. Canadian Journal of Cardiology, 2016, 32, 226-233.	0.8	51
243	Predictors and Implications of Coronary Infarct Artery Patency at Initial Angiography in Patients With Acute Myocardial Infarction (from the CADILLAC and HORIZONS-AMI Trials). American Journal of Cardiology, 2011, 108, 918-923.	0.7	50
244	Comparison of Three-Year Outcomes After Primary Percutaneous Coronary Intervention in Patients With Left Ventricular Ejection Fraction <40% Versus â‰¥40% (from the HORIZONS-AMI Trial). American Journal of Cardiology, 2013, 111, 12-20.	0.7	50
245	Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction. Journal of the American College of Cardiology, 2011, 57, 2309-2316.	1.2	49
246	The XIENCE nanoâ„¢ everolimus eluting coronary stent system for the treatment of small coronary arteries: The SPIRIT small vessel trial. Catheterization and Cardiovascular Interventions, 2012, 80, 546-553.	0.7	49
247	Intra-Procedural Stent Thrombosis. JACC: Cardiovascular Interventions, 2013, 6, 36-43.	1.1	49
248	D-dimer levels predict ischemic and hemorrhagic outcomes after acute myocardial infarction: a HORIZONS-AMI biomarker substudy. Journal of Thrombosis and Thrombolysis, 2014, 37, 155-164.	1.0	49
249	Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial. European Heart Journal, 2014, 35, 2524-2529.	1.0	49
250	Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention. JAMA Cardiology, 2020, 5, 21.	3.0	49
251	One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients. Circulation: Cardiovascular Interventions, 2020, 13, e009565.	1.4	49
252	Prognostic Impact of Race in Patients Undergoing PCI. JACC: Cardiovascular Interventions, 2020, 13, 1586-1595.	1.1	49

#	Article	IF	Citations
253	Diabetes Mellitus, Myocardial Reperfusion, and Outcome in Patients With Acute ST-Elevation Myocardial Infarction Treated With Primary Angioplasty (from HORIZONS AMI). American Journal of Cardiology, 2012, 109, 1111-1116.	0.7	48
254	Adverse event rates following primary PCI for STEMI at US and non-US hospitals: three-year analysis from the HORIZONS-AMI trial. EuroIntervention, 2013, 8, 1134-1142.	1.4	48
255	Coronary Pressureâ€"Derived Fractional Flow Reserve Measurements. Circulation: Cardiovascular Interventions, 2012, 5, 312-317.	1.4	47
256	Inverse relationship between body mass index and coronary artery calcification in patients with clinically significant coronary lesions. Atherosclerosis, 2012, 221, 176-182.	0.4	46
257	Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients. Circulation: Cardiovascular Interventions, 2015, 8, .	1.4	46
258	Impact of percutaneous coronary intervention extent, complexity and platelet reactivity on outcomes after drug-eluting stent implantation. International Journal of Cardiology, 2018, 268, 61-67.	0.8	46
259	Serial Intravascular Ultrasound Assessment of the Efficacy of Intracoronary Î³-Radiation Therapy for Preventing Recurrence in Very Long, Diffuse, In-Stent Restenosis Lesions. Circulation, 2001, 104, 856-859.	1.6	45
260	Outcomes of Patients with Coronary Artery Perforation Complicating Percutaneous Coronary Intervention and Correlations with the Type of Adjunctive Antithrombotic Therapy: Pooled Analysis from REPLACEâ€2, ACUITY, and HORIZONSâ€AMI Trials. Journal of Interventional Cardiology, 2009, 22, 453-459.	0.5	45
261	Predictors of Reperfusion Delay in Patients With Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention from the HORIZONS-AMI Trial. American Journal of Cardiology, 2010, 106, 1527-1533.	0.7	45
262	Prognostic Utility of Left Ventricular End-Diastolic Pressure in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. American Journal of Cardiology, 2011, 108, 1068-1074.	0.7	45
263	Long-Term Clinical Outcomes After Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Ostial/Midshaft Lesions in Unprotected Left Main Coronary Artery From the DELTA Registry. JACC: Cardiovascular Interventions, 2014, 7, 354-361.	1.1	45
264	Impact of Cigarette Smoking on Extent of Coronary Artery Disease and Prognosis of Patients With Nonâ€"ST-Segment Elevation Acute Coronary Syndromes. JACC: Cardiovascular Interventions, 2014, 7, 372-379.	1.1	45
265	Cerebral Embolism During TranscatheterÂAortic Valve Replacement. Journal of the American College of Cardiology, 2016, 68, 589-599.	1.2	45
266	Reperfusion strategies in acute myocardial infarction and multivessel disease. Nature Reviews Cardiology, 2017, 14, 665-678.	6.1	45
267	Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 677-686.	1.4	45
268	Treatment of focal in-stent restenosis with balloon angioplasty alone versus stenting: Short- and long-term results. American Heart Journal, 2001, 141, 610-614.	1.2	44
269	Usefulness of Minimum Stent Cross Sectional Area as a Predictor of Angiographic Restenosis After Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction (from the HORIZONS-AMI) Tj ETQq1 1 0.784314 rgBT /Ov	0.7	44
270	Non-Fibroatheroma Lesion Phenotype and Long-Term Clinical Outcomes. JACC: Cardiovascular Imaging, 2013, 6, 908-916.	2.3	44

#	Article	IF	Citations
271	Relationship Between Intravascular Ultrasound Guidance and Clinical Outcomes After Drug-Eluting Stents. Circulation: Cardiovascular Interventions, 2018, 11, e006243.	1.4	44
272	Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery. Journal of the American College of Cardiology, 2005, 45, 1186-1192.	1.2	43
273	Relation Between Angiographic Lesion Severity, Vulnerable Plaque Morphology and Future Adverse Cardiac Events (from the Providing Regional Observations to Study Predictors of Events in the) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.2	43
274	Sex-Based Differences in AcuteÂCoronaryÂSyndromes. JACC: Cardiovascular Imaging, 2016, 9, 451-464.	2.3	43
275	Optimal P2Y 12 Inhibitor in Patients WithÂST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2016, 9, 1036-1046.	1.1	42
276	Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management. Nature Reviews Cardiology, 2021, 18, 37-57.	6.1	42
277	Radial versus femoral access for coronary interventions: An updated systematic review and metaâ€analysis of randomized trials. Catheterization and Cardiovascular Interventions, 2021, 97, 1387-1396.	0.7	42
278	Impact of infarct-related artery patency before primary PCI on outcome in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. EuroIntervention, 2013, 8, 1307-1314.	1.4	42
279	Long-Term Clinical Outcomes of Percutaneous Coronary Intervention for Chronic Total Occlusions in Patients With Versus Without Diabetes Mellitus. American Journal of Cardiology, 2011, 108, 924-931.	0.7	41
280	Impact of the Severity of Coronary Artery Calcification on Clinical Events in Patients Undergoing Coronary Artery Bypass Grafting (from the Acute Catheterization and Urgent Intervention Triage) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.1	41
281	2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials. Journal of Nuclear Cardiology, 2015, 22, 1041-1144.	1.4	41
282	The DELTA 2 Registry. JACC: Cardiovascular Interventions, 2017, 10, 2401-2410.	1.1	41
283	Comparison of Direct Stenting With Conventional Stent Implantation in Acute Myocardial Infarction. American Journal of Cardiology, 2011, 108, 1697-1703.	0.7	40
284	Autopsy Validation Study of the Academic Research Consortium Stent Thrombosis Definition. JACC: Cardiovascular Interventions, 2011, 4, 554-559.	1.1	40
285	Residual Plaque Burden in Patients With Acute Coronary Syndromes After Successful Percutaneous Coronary Intervention. JACC: Cardiovascular Imaging, 2012, 5, S76-S85.	2.3	40
286	Women in interventional cardiology: Update in percutaneous coronary intervention practice patterns and outcomes of female operators from the National Cardiovascular Data RegistryÂ®. Catheterization and Cardiovascular Interventions, 2016, 87, 663-668.	0.7	40
287	Incidence and impact of acute kidney injury in patients with acute coronary syndromes treated with coronary artery bypass grafting: Insights from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) and Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trials. American Heart Journal, 2016, 171, 40-47.	1.2	40
288	Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention in Patients With Nonâ€“ST-Segment Elevation Acute Coronary Syndromes Are Associated With Adverse Outcomes. Journal of the American College of Cardiology, 2012, 59, 1745-1751.	1.2	39

#	Article	IF	Citations
289	Relationship Between ST-Segment Recovery and Clinical Outcomes After Primary Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2013, 6, 216-223.	1.4	39
290	Relation of Baseline Hemoglobin Levels and Adverse Events in Patients With Acute Coronary Syndromes (from the Acute Catheterization and Urgent Intervention Triage strategY and Harmonizing) Tj ETQq0 0 0 rgBT /Overlock 10 T of Cardiology, 2017, 119, 1710-1716.	0.7	39
291	Predictors of suboptimal TIMI flow after primary angioplasty for acute myocardial infarction: results from the HORIZONS-AMI trial. EuroIntervention, 2013, 9, 220-227.	1.4	39
292	Duration of Dual Antiplatelet Therapy forÂPatients at High Bleeding Risk Undergoing PCI. Journal of the American College of Cardiology, 2021, 78, 2060-2072.	1.2	39
293	Predictors and Implications of Stent Thrombosis in Nonâ€“ST-Segment Elevation Acute Coronary Syndromes. Circulation: Cardiovascular Interventions, 2011, 4, 577-584.	1.4	38
294	Comparison of clinical and angiographic prognostic risk scores in patients with acute coronary syndromes: Analysis from the Acute Catheterization and Urgent Intervention Triage StrategY (ACUITY) trial. American Heart Journal, 2012, 163, 383-391.e5.	1.2	38
295	Body Mass Index and Acute and Long-Term Outcomes After Acute Myocardial Infarction (from the) Tj ETQq1 1 0.784314 rgBT /Overlock American Journal of Cardiology, 2014, 114, 9-16.	0.7	38
296	Dual Antiplatelet Therapy Duration and Clinical Outcomes Following Treatment With Zotarolimus-Eluting Stents. JACC: Cardiovascular Interventions, 2011, 4, 1119-1128.	1.1	37
297	Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: Results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. American Heart Journal, 2011, 161, 298-306.e1.	1.2	37
298	A New Score for Risk Stratification of Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2012, 5, 1108-1116.	1.1	37
299	Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention WithÂStents. JACC: Cardiovascular Interventions, 2016, 9, 1461-1469.	1.1	37
300	A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: Design and rationale of the RADAR Phase IIb trial. American Heart Journal, 2011, 161, 261-268.e2.	1.2	36
301	Prognostic Utility of the SYNTAX Score in Patients With Single Versus Multivessel Disease Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage) Tj ETQq1 1 0.784314 rgBT /Ove	0.7	36
302	Impact of calcification on percutaneous coronary intervention: MACEâ€Trial 1â€year results. Catheterization and Cardiovascular Interventions, 2019, 94, 187-194.	0.7	36
303	Outcome of Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention During On- Versus Off-hours (A Harmonizing Outcomes With) Tj ETQq1 1 0.784314 rgBT /Overlock American Journal of Cardiology, 2013, 111, 946-954.	0.7	35
304	Outcomes in Patients With ST-Segment Elevation Acute MyocardialÂInfarction Treated With Clopidogrel Versus Prasugrel (from the INFUSE-AMI Trial). American Journal of Cardiology, 2014, 113, 1457-1460.	0.7	35
305	The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2016, 9, 1450-1457.	1.1	35
306	Percutaneous Coronary Intervention of Saphenous Vein Graft. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	35

#	Article	IF	Citations
307	Trial Design Principles for Patients at HighÂBleeding Risk Undergoing PCI. Journal of the American College of Cardiology, 2020, 76, 1468-1483.	1.2	35
308	Predictors of Outcomes in Medically Treated Patients With Acute Coronary Syndromes After Angiographic Triage. Circulation, 2010, 121, 853-862.	1.6	34
309	Impact of Diabetes Mellitus on the Safety and Effectiveness of Bivalirudin in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty. JACC: Cardiovascular Interventions, 2011, 4, 760-768.	1.1	34
310	Prognostic Value of Access Site and Nonaccess Site Bleeding After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2014, 7, 622-630.	1.1	34
311	Contemporary overview and clinical perspectives of chronic total occlusions. Nature Reviews Cardiology, 2014, 11, 458-469.	6.1	33
312	Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: A proposal from the Academic Bleeding Consensus (ABC) Multidisciplinary Working Group. American Heart Journal, 2009, 158, 881-886.e1.	1.2	32
313	Safety and Efficacy of High- Versus Low-Dose Aspirin After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2012, 5, 1231-1238.	1.1	32
314	Association Between Intraprocedural Thrombotic Events and Adverse Outcomes After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction (a Harmonizing) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.7	32
315	The relationship among extent of lipid-rich plaque, lesion characteristics, and plaque progression/regression in patients with coronary artery disease: a serial near-infrared spectroscopy and intravascular ultrasound study. European Heart Journal Cardiovascular Imaging, 2015, 16, 81-87.	0.5	32
316	SYNTAX score and the risk of stent thrombosis after percutaneous coronary intervention in patients with nonâ€ST–segment elevation acute coronary syndromes: An ACUITY trial substudy. Catheterization and Cardiovascular Interventions, 2015, 85, 1-10.	0.7	32
317	Incidence, Predictors, and Outcomes of High-Grade Atrioventricular Block in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (from the HORIZONS-AMI Trial). American Journal of Cardiology, 2017, 119, 1295-1301.	0.7	32
318	White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	32
319	Three-year clinical results of the Axxess Biolimus A9 eluting bifurcation stent system: the DIVERGE study. EuroIntervention, 2013, 9, 573-581.	1.4	32
320	Prognostic Significance of Coronary Thrombus in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes. JACC: Cardiovascular Interventions, 2011, 4, 769-777.	1.1	31
321	Randomized comparison between 3-month Cre8 DES vs. 1-month Vision/Multilink8 BMS neointimal coverage assessed by OCT evaluation: The DEMONSTRATE study. International Journal of Cardiology, 2014, 176, 904-909.	0.8	31
322	Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in PatientsÂUndergoing Percutaneous Coronary Intervention?. JACC: Cardiovascular Interventions, 2015, 8, 1978-1987.	1.1	31
323	Rationale and design of the Onyx ONE global randomized trial: A randomized controlled trial of high-bleeding risk patients after stent placement with 1â€month of dual antiplatelet therapy. American Heart Journal, 2019, 214, 134-141.	1.2	31
324	Long-Term Clinical Impact of Contrast-Associated Acute Kidney Injury Following PCI. JACC: Cardiovascular Interventions, 2022, 15, 753-766.	1.1	31

#	Article	IF	Citations
325	First-in-Man 1-Year Clinical Outcomes of the Catania Coronary Stent System With Nanothin Polyzene-F in De Novo Native Coronary Artery Lesions. JACC: Cardiovascular Interventions, 2009, 2, 197-204.	1.1	30
326	Percutaneous recanalization of chronic total occlusions: Wherein lies the body of proof?. American Heart Journal, 2013, 165, 133-142.	1.2	30
327	Meta-Analysis of Randomized Trials Comparing the Effectiveness of Different Strategies for the Treatment of Drug-Eluting Stent Restenosis. American Journal of Cardiology, 2014, 114, 1339-1346.	0.7	30
328	Impact of Bleeding and Bivalirudin Therapy on Mortality Risk in Women Undergoing Percutaneous Coronary Intervention (from the REPLACE-2, ACUITY, and HORIZONS-AMI Trials). American Journal of Cardiology, 2016, 117, 186-191.	0.7	30
329	Reasonable incomplete revascularisation after percutaneous coronary intervention: the SYNTAX Revascularisation Index. EuroIntervention, 2015, 11, 634-642.	1.4	30
330	P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. Nature Reviews Cardiology, 2022, 19, 829-844.	6.1	30
331	Bivalirudin Versus Heparin Plus a Glycoprotein IIb/IIIa Inhibitor in Patients With Nonâ€“ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment. Circulation: Cardiovascular Interventions, 2012, 5, 705-712.	1.4	29
332	Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients TreatedÂWith Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2017, 10, 1607-1617.	1.1	29
333	Intravascular Ultrasoundâ€”Guided Renal Artery Stenting. Journal of Endovascular Therapy, 2001, 8, 238-247.	0.8	28
334	Impact of Smoking on Outcomes of Patients With ST-Segment Elevation Myocardial Infarction (from) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.7	28
335	Complementary prognostic utility of myocardial blush grade and ST-segment resolution after primary percutaneous coronary intervention: Analysis from the HORIZONS-AMI trial. American Heart Journal, 2013, 166, 676-683.	1.2	28
336	Balancing the Risk of Bleeding and Stroke in Patients WithÂAtrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry). American Journal of Cardiology, 2015, 116, 37-42.	0.7	28
337	Preventing Contrast-induced Renal Failure: A Guide. Interventional Cardiology Review, 2016, 11, 98.	0.7	28
338	Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk. Circulation, 2020, 141, 891-901.	1.6	28
339	Comparison of the angiographic outcomes after beta versus gamma vascular brachytherapy for treatment of in-stent restenosis. American Journal of Cardiology, 2003, 92, 1409-1413.	0.7	27
340	Clinical and Angiographic Evaluation of the Resolute Zotarolimus-Eluting Coronary Stent in Japanese Patients. Circulation Journal, 2014, 79, 96-103.	0.7	27
341	Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	27
342	Comparison of Outcomes and Prognosis of Patients With Versus Without Newly Diagnosed Diabetes Mellitus After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (the HORIZONS-AMI Study). American Journal of Cardiology, 2017, 119, 1917-1923.	0.7	27

#	Article	IF	Citations
343	Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI. JACC: Cardiovascular Interventions, 2021, 14, 444-456.	1.1	27
344	Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention. JAMA Cardiology, 2021, 6, 1032.	3.0	27
345	Long-Term Outcomes of Percutaneous Coronary Interventions or Coronary Artery Bypass Grafting for Left Main Coronary Artery Disease in Octogenarians (from a Drug-Eluting stent for LefT main) Tj ETQq1 1 0.784314 rgBT /Overlock	3.1	26
346	The impact of the coronary collateral circulation on outcomes in patients with acute coronary syndromes: results from the ACUITY trial. Heart, 2014, 100, 647-651.	1.2	26
347	Surgical Versus Percutaneous Coronary Revascularization for Multivessel Disease in Diabetic Patients With Nonâ€“ST-Segmentâ€“Elevation Acute Coronary Syndrome. Circulation: Cardiovascular Interventions, 2015, 8, .	1.4	26
348	Resistant inâ€stent restenosis in the drug eluting stent era. Catheterization and Cardiovascular Interventions, 2016, 88, 777-785.	0.7	26
349	Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study. EuroIntervention, 2014, 10, 431-438.	1.4	26
350	Clinical outcomes of compromised side branch (stent jail) after coronary stenting with the NIR stent. Catheterization and Cardiovascular Interventions, 2001, 54, 295-300.	0.7	25
351	Successful use of the frontrunner catheter in the treatment of in-stent coronary chronic total occlusions. Catheterization and Cardiovascular Interventions, 2004, 63, 462-468.	0.7	25
352	Bleeding events are associated with an increase in markers of inflammation in acute coronary syndromes: an ACUITY trial substudy. Journal of Thrombosis and Thrombolysis, 2011, 31, 139-145.	1.0	25
353	Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction. American Heart Journal, 2016, 180, 22-28.	1.2	25
354	Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction. JAMA Cardiology, 2017, 2, 855.	3.0	25
355	Computed tomography predictors of mortality, stroke and conduction disturbances in women undergoing TAVR: A sub-analysis of the WIN-TAVI registry. Journal of Cardiovascular Computed Tomography, 2018, 12, 338-343.	0.7	25
356	Effect of Procedure and Coronary LesionÂCharacteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 626-634.	1.1	25
357	Definitions and Standardized Endpoints for Treatment of Coronary Bifurcations. Journal of the American College of Cardiology, 2022, 80, 63-88.	1.2	25
358	Safety of Intracoronary Î³-Radiation on Uninjured Reference Segments During the First 6 Months After Treatment of In-Stent Restenosis. Circulation, 2000, 101, 2227-2230.	1.6	24
359	Effect of percutaneous coronary interventions for in-stent restenosis in degenerated saphenous vein grafts without distal embolic protection. Journal of the American College of Cardiology, 2003, 41, 749-752.	1.2	24
360	Current periprocedural anticoagulation in transcatheter aortic valve replacement: could bivalirudin be an option? Rationale and design of the BRAVO 2/3 studies. Journal of Thrombosis and Thrombolysis, 2013, 35, 483-493.	1.0	24

#	Article	IF	Citations
361	Longâ€term clinical outcomes after percutaneous coronary intervention for chronic total occlusions in elderly patients (â‰¥75 Years). Catheterization and Cardiovascular Interventions, 2013, 82, 85-92.	0.7	24
362	Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2018, 11, e006144.	1.4	24
363	Real world safety and efficacy of the Janus tacrolimusâ€eluting stent: Longâ€term clinical outcome and angiographic findings from the tacrolimusâ€eluting stent (TEST) registry. Catheterization and Cardiovascular Interventions, 2009, 73, 243-248.	0.7	23
364	Relationship between angiographic dynamic and densitometric assessment of myocardial reperfusion and survival in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: The Harmonizing Outcomes with Revascularization and Stents in AMI (HORIZONS-AMI) trial. American Heart Journal, 2011, 162, 1044-1051.	1.2	23
365	Correlation between index electrocardiographic patterns and preâ€intervention angiographic findings: Insights from the HORIZONSâ€AMI trial. Catheterization and Cardiovascular Interventions, 2012, 79, 1092-1098.	0.7	23
366	Comparison of Outcomes of Patients With ST-Segment Elevation Myocardial Infarction With Versus Without Previous Coronary Artery Bypass Grafting (from the Harmonizing Outcomes With) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 542 Tc of Cardiology, 2013, 111, 1377-1386.	0.7	23
367	Procedural variation in the performance of primary percutaneous coronary intervention for STâ€elevation myocardial infarction: A SCAIâ€based survey study of US interventional cardiologists. Catheterization and Cardiovascular Interventions, 2014, 83, 721-726.	0.7	23
368	Relation of C-Reactive Protein Levels to Instability of Untreated Vulnerable Coronary Plaques (from) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.7	23
369	Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium. European Journal of Heart Failure, 2020, 22, 2175-2186.	2.9	23
370	Sexâ€Based Differences in Bleeding Risk After Percutaneous Coronary Intervention and Implications for the Academic Research Consortium High Bleeding Risk Criteria. Journal of the American Heart Association, 2021, 10, e021965.	1.6	23
371	Intravascular Ultrasoundâ€“Guided Renal Artery Stenting. Journal of Endovascular Therapy, 2001, 8, 238-247.	0.8	23
372	Evolution of drug-eluting coronary stents: a back-and-forth journey from the bench to bedside. Cardiovascular Research, 2023, 119, 631-646.	1.8	23
373	Balancing ischaemia and bleeding risks with novel oral anticoagulants. Nature Reviews Cardiology, 2014, 11, 693-703.	6.1	22
374	Relation Between Coronary Calcium and Major Bleeding After Percutaneous Coronary Intervention in Acute Coronary Syndromes (from the Acute Catheterization and Urgent Intervention Triage Strategy) Tj ETQq0 0 0 rgBT /Overlock 10 Tf American Journal of Cardiology, 2014, 113, 930-935.	0.7	22
375	Incidence and Impact of Totally Occluded Culprit Coronary Arteries in Patients Presenting With Nonâ€“ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2015, 115, 428-433.	0.7	22
376	Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. Canadian Journal of Cardiology, 2018, 34, 319-329.	0.8	22
377	Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 492-502.	1.4	22
378	Effect of bivalirudin on aortic valve intervention outcomes study: a two-centre registry study comparing bivalirudin and unfractionated heparin in balloon aortic valvuloplasty. EuroIntervention, 2014, 10, 312-319.	1.4	22

#	Article	IF	Citations
379	Sex-Specific Considerations in the Presentation, Diagnosis, and Management of Ischemic Heart Disease. Journal of the American College of Cardiology, 2022, 79, 1398-1406.	1.2	22
380	Drug-Eluting Stents in the Real World: How Intravascular Ultrasound Can Improve Clinical Outcome. American Journal of Cardiology, 2008, 102, 24J-28J.	0.7	21
381	Impact of Bivalirudin Therapy in High-Risk Patients With Acute Myocardial Infarction. JACC: Cardiovascular Interventions, 2010, 3, 796-802.	1.1	21
382	Predictive value of C-reactive protein on 30-day and 1-year mortality in acute coronary syndromes: an analysis from the ACUITY trial. Journal of Thrombosis and Thrombolysis, 2011, 31, 154-164.	1.0	21
383	1-Year Clinical Outcomes of All-Comer Patients Treated With the Dual-Therapy COMBO Stent. JACC: Cardiovascular Interventions, 2018, 11, 1969-1978.	1.1	21
384	Optimal Duration of Dual Antiplatelet Therapy After Left Main Coronary Stenting. Journal of the American College of Cardiology, 2018, 72, 2086-2087.	1.2	21
385	Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry. Clinical Research in Cardiology, 2019, 108, 643-650.	1.5	21
386	Sex-Based Outcomes in Patients With a High Bleeding Risk After Percutaneous Coronary Intervention and 1-Month Dual Antiplatelet Therapy. JAMA Cardiology, 2020, 5, 939.	3.0	21
387	Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2020, 13, e008226.	1.4	21
388	Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent. American Heart Journal, 2021, 231, 147-156.	1.2	21
389	Antithrombotic therapy after percutaneous coronary intervention of bifurcation lesions. EuroIntervention, 2021, 17, 59-66.	1.4	21
390	Gender differences on benefits and risks associated with oral antithrombotic medications for coronary artery disease. Expert Opinion on Drug Safety, 2018, 17, 1041-1052.	1.0	20
391	Nonculprit Lesion Severity and Outcome of Revascularization in Patients With STEMI and Multivessel Coronary Disease. Journal of the American College of Cardiology, 2020, 76, 1277-1286.	1.2	20
392	Comparison of Bivalirudin Versus Bivalirudin Plus Glycoprotein IIb/IIIa Inhibitor Versus Heparin Plus Glycoprotein IIb/IIIa Inhibitor in Patients With Acute Coronary Syndromes Having Percutaneous Intervention for Narrowed Saphenous Vein Aorto-Coronary Grafts (the ACUITY Trial Investigators). American Journal of Cardiology, 2010, 106, 941-945.	0.7	19
393	Prognostic Significance of Elevated Baseline Troponin in Patients With Acute Coronary Syndromes and Chronic Kidney Disease Treated With Different Antithrombotic Regimens. Circulation: Cardiovascular Interventions, 2012, 5, 157-165.	1.4	19
394	Usefulness of the SYNTAX Score to Predict Acute Kidney Injury After Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial). American Journal of Cardiology, 2014, 113, 1331-1337.	0.7	19
395	Determinants of Significant Out-Of-Hospital Bleeding in Patients Undergoing Percutaneous Coronary Intervention. Thrombosis and Haemostasis, 2018, 118, 1997-2005.	1.8	19
396	Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). American Journal of Cardiology, 2018, 122, 1638-1646.	0.7	19

#	Article	IF	Citations
397	Safety and efficacy of the COMBO bio-engineered stent in an all-comer PCI cohort: 1-Year final clinical outcomes from the MASCOT post-marketing registry. International Journal of Cardiology, 2019, 283, 67-72.	0.8	19
398	Usefulness of Clopidogrel Loading in Patients Who Underwent Transcatheter Aortic Valve Implantation (from the BRAVO-3 Randomized Trial). American Journal of Cardiology, 2019, 123, 1494-1500.	0.7	19
399	Stent Thrombosis Risk Over Time on the Basis of Clinical Presentation and PlateletÂReactivity. JACC: Cardiovascular Interventions, 2021, 14, 417-427.	1.1	19
400	Relation Between Platelet Count and Platelet Reactivity to Thrombotic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. American Journal of Cardiology, 2016, 117, 1703-1713.	0.7	18
401	Sex Difference in Chest Pain After Implantation of Newer Generation Coronary Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2016, 9, 553-561.	1.1	18
402	Shortâ€versus longâ€term Dual Antiplatelet therapy after drugâ€eluting stent implantation in women versus men: A sexâ€specific patientâ€level pooledâ€analysis of six randomized trials. Catheterization and Cardiovascular Interventions, 2017, 89, 178-189.	0.7	18
403	CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I: safety and tolerability profiles and implications for management in patients with myocardial infarction. Expert Opinion on Investigational Drugs, 2018, 27, 997-1005.	1.9	18
404	Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y₁₂Receptor Inhibitors With and Without Aspirin: Results of the VORAâ€PRATIC Study. Journal of the American Heart Association, 2020, 9, e015865.	1.6	18
405	Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. European Heart Journal, 2021, 42, 4683-4693.	1.0	18
406	Long-Term Follow-Up of Attenuated Plaques in Patients With Acute Myocardial Infarction. Circulation: Cardiovascular Interventions, 2012, 5, 185-192.	1.4	17
407	Leukocyte Count Is a Modulating Factor for the Mortality Benefit of Bivalirudin in ST-Segmentâ€"Elevation Acute Myocardial Infarction. Circulation: Cardiovascular Interventions, 2013, 6, 518-526.	1.4	17
408	Comparison of Prasugrel and Bivalirudin vs Clopidogrel and Heparin in Patients With <scp>ST</scp>â€Segment Elevation Myocardial Infarction: Design and Rationale of the Bavarian Reperfusion Alternatives Evaluation (<scp>BRAVE</scp>) 4 Trial. Clinical Cardiology, 2014, 37, 270-276.	0.7	17
409	Which Intraprocedural Thrombotic Events Impact Clinical Outcomes After Percutaneous Coronary Intervention inÂAcute Coronary Syndromes?. JACC: Cardiovascular Interventions, 2016, 9, 331-337.	1.1	17
410	Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and RiskÂfor Adverse EventsÂAmong Patients With and WithoutÂDiabetes Mellitus Receiving Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2017, 10, 645-654.	1.1	17
411	Quantifying Ischemic Risk After Percutaneous Coronary Intervention Attributable to High Platelet Reactivity on Clopidogrel (From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents) Tj ETQq1 1 0.784314 rgBT /Ov	0.7	17
412	Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population. Circulation: Cardiovascular Interventions, 2018, 11, e006853.	1.4	17
413	Design and rationale of the COMPLETE trial: A randomized, comparative effectiveness study of complete versus culprit-only percutaneous coronary intervention to treat multivessel coronary artery disease in patients presenting with ST-segment elevation myocardial infarction. American Heart Journal, 2019, 215, 157-166.	1.2	17
414	Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2019, 12, e007133.	1.4	17

#	Article	IF	Citations
415	Impact of Pre-Diabetes on Coronary Plaque Composition and Clinical OutcomeÂin Patients With Acute CoronaryÂSyndromes. JACC: Cardiovascular Imaging, 2019, 12, 733-741.	2.3	17
416	Impact of Percutaneous Coronary Intervention on Outcomes in Patients With HeartÂFailure. Journal of the American College of Cardiology, 2021, 77, 2432-2447.	1.2	17
417	Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for acute coronary syndrome from the DELTA registry: a multicentre registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. EuroIntervention, 2016, 12, e623-e631.	1.4	17
418	Impact of bifurcation target lesion on angiographic, electrocardiographic, and clinical outcomes of patients undergoing primary percutaneous coronary intervention (from the Harmonizing Outcomes) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 EuroIntervention, 2013, 9, 817-823.	1.4	17
419	Usefulness of beta radiation for de novo and In-Stent restenotic lesions in saphenous vein grafts. American Journal of Cardiology, 2003, 92, 312-314.	0.7	16
420	Association Among Leukocyte Count, Mortality, and Bleeding in Patients With Nonâ€“ST-Segment Elevation Acute Coronary Syndromes (from the Acute Catheterization and Urgent Intervention Triage) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.7	16
421	The use of vascular closure devices and impact on major bleeding and net adverse clinical events (NACEs) in balloon aortic valvuloplasty: A subâ€analysis of the BRAVO study. Catheterization and Cardiovascular Interventions, 2014, 83, 148-153.	0.7	16
422	Comparison of Outcomes in Patients With ST-Segment Elevation Myocardial Infarction Discharged on Versus Not on Statin Therapy (from the Harmonizing Outcomes With Revascularization and Stents in) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.7	16
423	Impact of Hemoglobin A1c Levels on Residual Platelet Reactivity and Outcomes After Insertion of Coronary Drug-Eluting Stents (from the ADAPT-DES Study). American Journal of Cardiology, 2016, 117, 192-200.	0.7	16
424	Angiographic predictors of 2â€year stent thrombosis in patients receiving drugâ€eluting stents: Insights from the <scp>ADAPTâ€DES</scp> study. Catheterization and Cardiovascular Interventions, 2017, 89, 26-35.	0.7	16
425	Predictors of Left Ventricular Ejection Fraction Improvement After Primary Stenting in ST-Segment Elevation Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents) Tj ETQq1 1 0.784314 rgBT /Over	0.7	16
426	The prevalence, predictors and outcomes of guidelineâ€directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry. Catheterization and Cardiovascular Interventions, 2019, 93, E112-E119.	0.7	16
427	Benefits of optimising coronary flow before stenting in primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from INFUSE-AMI. EuroIntervention, 2014, 9, 1195-1201.	1.4	16
428	Bridging Antiplatelet Therapy After Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2021, 78, 1550-1563.	1.2	16
429	Percutaneous Transcatheter Management of Giant Coronary Aneurysms. Circulation, 1999, 100, E8-E11.	1.6	15
430	Impact of Transfer for Primary Percutaneous Coronary Intervention on Survival and Clinical Outcomes (from the HORIZONS-AMI Trial). American Journal of Cardiology, 2010, 106, 1218-1224.	0.7	15
431	Clustering of Acute and Subacute Stent Thrombosis Related to the Introduction of Generic Clopidogrel. Journal of Cardiovascular Pharmacology and Therapeutics, 2014, 19, 201-208.	1.0	15
432	Outcomes of Patients Calling Emergency Medical Services for Suspected Acute Cardiovascular Disease. American Journal of Cardiology, 2015, 115, 13-20.	0.7	15

#	Article	IF	Citations
433	Outcomes in elderly and young patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin: Pooled analysis from the EUROMAX and HORIZONS-AMI trials. American Heart Journal, 2017, 194, 73-82.	1.2	15
434	Standardized Definitions for EvaluationÂofÂHeart Failure Therapies: Scientific Expert Panel From the HeartÂFailure Collaboratory and Academic Research Consortium. JACC: Heart Failure, 2020, 8, 961-972.	1.9	15
435	Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. JAMA Cardiology, 2022, 7, 747.	3.0	15
436	Relationship between biomarkers and subsequent clinical and angiographic restenosis after paclitaxel-eluting stents for treatment of STEMI: a HORIZONS-AMI substudy. Journal of Thrombosis and Thrombolysis, 2012, 34, 165-179.	1.0	14
437	Femoral vascular closure device use, bivalirudin anticoagulation, and bleeding after primary angioplasty for STEMI: Results from the <scp>HORIZONS</scp>â€<scp>AMI</scp> trial. Catheterization and Cardiovascular Interventions, 2015, 85, 371-379.	0.7	14
438	Predictors and impact of target vessel revascularization after stent implantation for acute ST-segment elevation myocardial infarction: Lessons from HORIZONS-AMI. American Heart Journal, 2015, 169, 242-248.	1.2	14
439	Utility of post-procedural anticoagulation after primary PCI for STEMI: insights from a pooled analysis of the HORIZONS-AMI and EUROMAX trials. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 659-665.	0.4	14
440	Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	14
441	Correlation of Admission Heart Rate With Angiographic and Clinical Outcomes in Patients With Right Coronary Artery STâ€Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: HORIZONSâ€AMI (The Harmonizing Outcomes With Revascularization and Stents) Tj ETQq1 1 0.784314 rgBT	1.6	14
442	Platelet Reactivity and Risk of IschemicÂStroke After Coronary Drug-Eluting StentÂImplantation. JACC: Cardiovascular Interventions, 2018, 11, 1277-1286.	1.1	14
443	Coronary artery stenting. Catheterization and Cardiovascular Interventions, 2002, 56, 83-102.	0.7	13
444	How Serious a Problem is Bleeding in Patients with Acute Coronary Syndromes?. Current Cardiology Reports, 2011, 13, 312-319.	1.3	13
445	Fixed and Modifiable Correlates of Drug-Eluting Stent Thrombosis From a Large All-Comers Registry. Circulation: Cardiovascular Interventions, 2015, 8, .	1.4	13
446	Usefulness of the Left Anterior Descending Coronary Artery Wrapping Around the Left Ventricular Apex to Predict Adverse Clinical Outcomes in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.7	13
447	Early Stent Thrombosis and Mortality After Primary Percutaneous Coronary Intervention in ST-Segmentâ€"Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2016, 9, e003272.	1.4	13
448	Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. Catheterization and Cardiovascular Interventions, 2017, 89, E217-E225.	0.7	13
449	Bleeding Severity After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2018, 11, e005542.	1.4	13
450	Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology. Thrombosis and Haemostasis, 2020, 120, 348-362.	1.8	13

#	Article	IF	Citations
451	Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI. JACC: Cardiovascular Interventions, 2021, 14, 1434-1446.	1.1	13
452	Serial Intravascular Ultrasound Analysis of the Impact of Myocardial Bridge on Neointimal Proliferation After Coronary Stenting in Patients with Acute Myocardial Infarction. Journal of Interventional Cardiology, 2010, 23, 114-122.	0.5	12
453	Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 121-128.	3.1	12
454	Impact of advanced age on the safety and effectiveness of paclitaxelâ€eluting stent implantation in patients with STâ€segment elevation myocardial infarction undergoing primary angioplasty. Catheterization and Cardiovascular Interventions, 2013, 82, 869-877.	0.7	12
455	Impact of Major Bleeding on Long-Term Mortality in Anemic Versus Nonanemic Patients Undergoing Percutaneous Coronary Intervention Using Bivalirudin. American Journal of Cardiology, 2014, 113, 1481-1486.	0.7	12
456	Age-Related Effects of Smoking on Coronary Artery Disease Assessed by Gray Scale and Virtual Histology Intravascular Ultrasound. American Journal of Cardiology, 2015, 115, 1056-1062.	0.7	12
457	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis. Circulation: Cardiovascular Interventions, 2016, 9, e002995.	1.4	12
458	Risk stratification of patients undergoing medical therapy after coronary angiography. European Heart Journal, 2016, 37, 3103-3110.	1.0	12
459	Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age. JACC: Cardiovascular Interventions, 2019, 12, 983-992.	1.1	12
460	Impact of Race and Ethnicity on the Clinical and Angiographic Characteristics, Social Determinants of Health, and 1-Year Outcomes After Everolimus-Eluting Coronary Stent Procedures in Women. Circulation: Cardiovascular Interventions, 2019, 12, e006918.	1.4	12
461	Sexâ€Related Differences in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention: A Patientâ€Level Pooled Analysis From 4 Postapproval Studies. Journal of the American Heart Association, 2020, 9, e014611.	1.6	12
462	Relationship between insulin resistance, coronary plaque, and clinical outcomes in patients with acute coronary syndromes: an analysis from the PROSPECT study. Cardiovascular Diabetology, 2021, 20, 10.	2.7	12
463	Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention. Journal of the American College of Cardiology, 2022, 79, 417-427.	1.2	12
464	Impact of Scheduled Angiographic Followâ€<scp>U</scp>p in Patients Treated With Primary Percutaneous Coronary Intervention for <scp>ST</scp>â€<scp>S</scp>egment Elevation Myocardial Infarction. Journal of Interventional Cardiology, 2013, 26, 319-324.	0.5	11
465	Compensatory enlargement of the left main coronary artery. Coronary Artery Disease, 2014, 25, 98-103.	0.3	11
466	Impact of Multiple Complex Plaques on Short- and Long-Term Clinical Outcomes in Patients Presenting With ST-Segment Elevation Myocardial Infarction (from the Harmonizing Outcomes With) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 142 Td of Cardiology, 2014, 113, 1621-1627.	0.7	11
467	Gender-specific outcomes after balloon aortic valvuloplasty: Inhospital and long-term outcomes. American Heart Journal, 2015, 170, 180-186.	1.2	11
468	Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. International Journal of Cardiology, 2017, 243, 132-139.	0.8	11

#	Article	IF	Citations
469	Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2019, 12, e007124.	1.4	11
470	Impact of insulin treated and nonâ€insulinâ€treated diabetes compared to patients without diabetes on 1â€year outcomes following contemporary PCI. Catheterization and Cardiovascular Interventions, 2020, 96, 298-308.	0.7	11
471	Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 648-659.	1.4	11
472	Quantitative angiographic characterisation of coronary artery disease in patients with human immunodeficiency virus (HIV) infection undergoing percutaneous coronary intervention. EuroIntervention, 2017, 12, 1757-1765.	1.4	11
473	Risk-Benefit of 1-Year DAPT After DES Implantation in Patients Stratified by Bleeding and Ischemic Risk. Journal of the American College of Cardiology, 2021, 78, 1968-1986.	1.2	11
474	Intravascular brachytherapy for native coronary ostial in-stent restenotic lesions. Journal of the American College of Cardiology, 2003, 41, 1725-1731.	1.2	10
475	Intravascular Ultrasound Findings of Stent Fractures in Patients With Sirolimus- and Paclitaxel-Eluting Stents. American Journal of Cardiology, 2010, 106, 952-957.	0.7	10
476	Paclitaxel-Eluting Stents Compared With Bare Metal Stents in Diabetic Patients With Acute Myocardial Infarction. Circulation: Cardiovascular Interventions, 2011, 4, 130-138.	1.4	10
477	Operator Versus Core Laboratory Assessment of Angiographic Reperfusion Markers in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segmentâ€"Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2012, 5, 563-569.	1.4	10
478	Relationship between the intensity of heparin anticoagulation and clinical outcomes in patients receiving glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction. Catheterization and Cardiovascular Interventions, 2013, 81, E9-14.	0.7	10
479	Characteristics and Outcomes of Patients With ST-Segment Elevation Myocardial Infarction Excluded from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial. American Journal of Cardiology, 2013, 111, 196-201.	0.7	10
480	Accuracy of bleeding scores for patients presenting with myocardial infarction: a meta-analysis of 9 studies and 13 759 patients. Postepy W Kardiologii Interwencyjnej, 2015, 3, 182-190.	0.1	10
481	Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of) Tj ETQq1 1 0.784314 rgBT /Ov 2017, 120, 904-910.	0.7	10
482	Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis, 2018, 46, 346-350.	1.0	10
483	Safety and efficacy of nonâ€"vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial. American Heart Journal, 2018, 203, 17-24.	1.2	10
484	The link between anemia and adverse outcomes in patients with acute coronary syndrome. Expert Review of Cardiovascular Therapy, 2019, 17, 151-159.	0.6	10
485	1-Year Clinical Outcomes of AllÂComersÂTreated With 2 Bioresorbable Polymer-Coated Sirolimus-Eluting Stents. JACC: Cardiovascular Interventions, 2020, 13, 820-830.	1.1	10
486	Polymer-Based Versus Polymer-Free Stents in High Bleeding Risk Patients. JACC: Cardiovascular Interventions, 2022, 15, 1153-1163.	1.1	10

#	Article	IF	Citations
487	Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacyâ€. European Heart Journal, 2013, 34, 1621-1629.	1.0	9
488	Clinical endpoint adjudication in a contemporary all-comers coronary stent investigation: Methodology and external validation. Contemporary Clinical Trials, 2013, 34, 53-59.	0.8	9
489	Coronary reperfusion and clinical outcomes after thrombus aspiration during primary percutaneous coronary intervention: Findings from the HORIZONSâ€AMI trial. Catheterization and Cardiovascular Interventions, 2013, 82, 594-601.	0.7	9
490	Comparisons of the uptake and in-hospital outcomes associated with second-generation drug-eluting stents between men and women. Coronary Artery Disease, 2016, 27, 442-448.	0.3	9
491	Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials. American Journal of Cardiology, 2016, 118, 6-16.	0.7	9
492	Prognostic implications of Q waves at presentation in patients with STâ€segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: An analysis of the HORIZONSâ€AMI study. Clinical Cardiology, 2017, 40, 982-987.	0.7	9
493	Percutaneous coronary intervention of bifurcation lesions and platelet reactivity. International Journal of Cardiology, 2018, 250, 92-97.	0.8	9
494	Predictors of mortality in patients with nonâ€anterior STâ€segment elevation myocardial infarction: Analysis from the HORIZONSâ€AMI trial. Catheterization and Cardiovascular Interventions, 2019, 94, 172-180.	0.7	9
495	Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. American Journal of Cardiology, 2019, 123, 709-716.	0.7	9
496	Design and Rationale of a Randomized Trial of COBRA PzF Stenting to REDUCE Duration of Triple Therapy (COBRA-REDUCE). Cardiovascular Revascularization Medicine, 2022, 34, 17-24.	0.3	9
497	Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention. Circulation, 2021, 143, 1215-1223.	1.6	9
498	Dual Antiplatelet Therapy Discontinuation, Platelet Reactivity, andÂAdverse Outcomes After Successful Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2022, 15, 797-806.	1.1	9
499	Changes in reference vessel diameter in ST-segment elevation myocardial infarction after primary percutaneous coronary intervention: Implications for appropriate stent sizing. American Heart Journal, 2011, 162, 173-177.	1.2	8
500	Evaluating the Bite of the BARC. Circulation, 2012, 125, 1344-1346.	1.6	8
501	Comparison of Abciximab Versus Eptifibatide During Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction (from the HORIZONS-AMI Trial). American Journal of Cardiology, 2012, 110, 940-947.	0.7	8
502	Implications of pre-procedural TIMI flow in patients with non ST-segment elevation acute coronary syndromes undergoing percutaneous coronary revascularization: Insights from the ACUITY trial. International Journal of Cardiology, 2013, 167, 727-732.	0.8	8
503	Frequency, Mechanisms, and Implications of Late Peri-Stent Contrast Staining: Analysis (from the) Tj ETQq1 1 0.784314 rgBT /Overlock	0.7	8
504	Clinical profile and impact of family history of premature coronary artery disease on clinical outcomes of patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: analysis from the HORIZONS-AMI Trial. Cardiovascular Revascularization Medicine, 2014, 15, 375-380.	0.3	8

#	Article	IF	Citations
505	Coronary Artery Revascularization in Chronic Kidney Disease. Circulation: Cardiovascular Interventions, 2015, 8, .	1.4	8
506	Prediction of 1â€year mortality and impact of bivalirudin therapy according to level of baseline risk: A patientâ€level pooled analysis from three randomized trials. Catheterization and Cardiovascular Interventions, 2016, 87, 391-400.	0.7	8
507	Pretreatment with aspirin in acute coronary syndromes: Lessons from the ACUITY and HORIZONS-AMI trials. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 449-454.	0.4	8
508	Impact of preâ€existing or newâ€onset atrial fibrillation on 30â€day clinical outcomes following transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial. Catheterization and Cardiovascular Interventions, 2017, 90, 1027-1037.	0.7	8
509	Percutaneous coronary intervention of lesions with in-stent restenosis: A report from the ADAPT-DES study. American Heart Journal, 2018, 197, 142-149.	1.2	8
510	Preprocedural anemia in females undergoing transcatheter aortic valve implantation: Insights from the WINâ€TAVI registry. Catheterization and Cardiovascular Interventions, 2021, 97, E704-E715.	0.7	8
511	Prognostic value of recurrent episodes of creatine kinase-MB elevation following repeated catheter-based coronary interventions. Catheterization and Cardiovascular Interventions, 2000, 51, 131-137.	0.7	7
512	Impact of in-hospital major bleeding on outcomes in acute coronary syndromes. Current Opinion in Cardiology, 2012, 27, 669-674.	0.8	7
513	Comparative effectiveness of upstream glycoprotein IIb/IIIa inhibitors in patients with moderate- and high-risk acute coronary syndromes: An Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy. American Heart Journal, 2014, 167, 43-50.	1.2	7
514	Antiplatelet therapy after drug-eluting stent implantation. Journal of Cardiology, 2015, 65, 98-104.	0.8	7
515	The Ideal Anticoagulation Strategy in ST-Elevation Myocardial Infarction. Progress in Cardiovascular Diseases, 2015, 58, 247-259.	1.6	7
516	Impact of Smoking on Platelet Reactivity and Clinical Outcomes After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2019, 12, e007982.	1.4	7
517	Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin. Circulation, 2019, 140, 1960-1963.	1.6	7
518	Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e004945.	0.9	7
519	Procedural and 1â€year clinical outcomes of orbital atherectomy for treatment of coronary inâ€stent restenosis: A singleâ€center, retrospective study. Catheterization and Cardiovascular Interventions, 2021, 97, E280-E287.	0.7	7
520	Incidence, predictors, and outcomes associated with acute kidney injury in patients undergoing transcatheter aortic valve replacement: from the BRAVO-3 randomized trial. Clinical Research in Cardiology, 2021, 110, 649-657.	1.5	7
521	Incidence, predictors and clinical impact of permanent pacemaker insertion in women following transcatheter aortic valve implantation: Insights from a prospective multinational registry. Catheterization and Cardiovascular Interventions, 2021, 98, E908-E917.	0.7	7
522	Are drug-eluting stents safe in the long term?. Cmaj, 2009, 180, 154-155.	0.9	6

#	Article	IF	Citations
523	Does clinical presentation affect outcome among patients with acute coronary syndromes undergoing percutaneous coronary intervention? Insights from the Providing Regional Observations to Study Predictors of Events in the Coronary Tree study. American Heart Journal, 2012, 164, 561-567.	1.2	6
524	Relationship between biomarkers and subsequent bleeding risk in ST-segment elevation myocardial infarction patients treated with paclitaxel-eluting stents: a HORIZONS-AMI substudy. Journal of Thrombosis and Thrombolysis, 2013, 35, 200-208.	1.0	6
525	Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse Outcomes. American Journal of Cardiology, 2016, 118, 1661-1668.	0.7	6
526	Is routine post-procedural anticoagulation warranted after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction? Insights from the HORIZONS-AMI trial. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 650-658.	0.4	6
527	Effect of Short Procedural Duration With Bivalirudin on Increased Risk of Acute Stent Thrombosis in Patients With STEMI. JAMA Cardiology, 2017, 2, 673.	3.0	6
528	Worsening atrioventricular conduction after hospital discharge in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Coronary Artery Disease, 2017, 28, 550-556.	0.3	6
529	Incidence, determinants and clinical impact of definite stent thrombosis on mortality in women: From the WIN-DES collaborative patient-level pooled analysis. International Journal of Cardiology, 2018, 263, 24-28.	0.8	6
530	Efficacy and safety of bivalirudin in coronary artery disease patients with mild to moderate chronic kidney disease: Meta-analysis. Journal of Cardiology, 2018, 71, 494-504.	0.8	6
531	Impact of high on-aspirin platelet reactivity on outcomes following successful percutaneous coronary intervention with drug-eluting stents. American Heart Journal, 2018, 205, 77-86.	1.2	6
532	Cost Implications of Anticoagulation Strategies After Percutaneous Coronary Intervention Among Patients With Atrial Fibrillation (A PIONEER-AF PCI Analysis). American Journal of Cardiology, 2019, 123, 355-360.	0.7	6
533	Impact of Point-of-Care Platelet Function Testing Among Patients With and Without Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents (from the) Tj ETQq1 1 0.784314 rgBT /Overlock	0.7	6
534	Impact of high onâ€treatment platelet reactivity on outcomes following PCI in patients on hemodialysis: An ADAPTâ€DES substudy. Catheterization and Cardiovascular Interventions, 2020, 96, 793-801.	0.7	6
535	Angiographic Restenosis in Coronary Bifurcations Treatment with Regular Drug Eluting Stents and Dedicated Bifurcation Drug-Eluting BiOSS Stents: Analysis Based on Randomized POLBOS I and POLBOS II Studies. Cardiovascular Therapeutics, 2020, 2020, 1-8.	1.1	6
536	Safety and efficacy of the bioabsorbable polymer everolimusâ€eluting stent versus durable polymer drugâ€eluting stents in highâ€risk patients undergoing PCI : TWILIGHTâ€SYNERGY. Catheterization and Cardiovascular Interventions, 2021, 97, 63-71.	0.7	6
537	Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI. JACC: Cardiovascular Interventions, 2022, 15, 282-293.	1.1	6
538	Dedicated two-stent technique in complex bifurcation percutaneous coronary intervention with use of everolimus-eluting stents: The EES-bifurcation study. International Journal of Cardiology, 2014, 174, 13-17.	0.8	5
539	Newâ€generation drugâ€eluting stents reduce stent thrombosis and myocardial infarction: A propensityâ€scoreâ€adjusted analysis from the multicenter REAL registry (REgistro Regionale) Tj ETQq1 1 0.784314 rgBT /Overlock 1 797-806.	0.7	5
540	Morphological changes and clinical impact of unstable plaques within untreated segments of acute myocardial infarction patients during a 3-year follow-up. Coronary Artery Disease, 2015, 26, 469-475.	0.3	5

#	Article	IF	Citations
541	Cost implications of intraprocedural thrombotic events during <scp>PCI</scp>. Catheterization and Cardiovascular Interventions, 2015, 86, 30-39.	0.7	5
542	Follow the Data. JACC: Cardiovascular Interventions, 2015, 8, 225-227.	1.1	5
543	Non-vitamin K Antagonist Oral Anticoagulant After Acute Coronary Syndrome: Is There a Role?. Interventional Cardiology Review, 2018, 13, 1.	0.7	5
544	Atrial fibrillation, with ACS and PCI: walking a tightrope. European Heart Journal, 2019, 40, 1563-1566.	1.0	5
545	Associations between use of prasugrel vs clopidogrel and outcomes by type of acute coronary syndrome: an analysis from the PROMETHEUS registry. Journal of Thrombosis and Thrombolysis, 2019, 48, 42-51.	1.0	5
546	Clinical outcomes after TAVR with heparin or bivalirudin as periprocedural anticoagulation in patients with and without peripheral arterial disease: Results from the BRAVOâ€3 randomized trial. Catheterization and Cardiovascular Interventions, 2020, 96, E377-E386.	0.7	5
547	Comparison of One-Year Outcomes in Patients >75 Versus â‰75 Years With Coronary Artery Disease Treated With COMBO Stents (From The MASCOT Registry). American Journal of Cardiology, 2020, 127, 1-8.	0.7	5
548	Abluminus DES+ for the treatment of coronary artery disease in patients with diabetes mellitus. Future Cardiology, 2020, 16, 613-623.	0.5	5
549	Clinical event committees in coronary stent trials: insights and recommendations based on experience in an unselected study population. EuroIntervention, 2012, 8, 368-374.	1.4	5
550	Incidence, predictors, and impact of neurological events in non-ST-segment elevation acute coronary syndromes: the ACUITY trial. EuroIntervention, 2015, 11, 399-406.	1.4	5
551	Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 707-716.	1.4	5
552	Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study. EuroIntervention, 2022, 17, 1330-1339.	1.4	5
553	Intracoronary brachytherapy not associated with changes in major side branches. Catheterization and Cardiovascular Interventions, 2000, 51, 154-158.	0.7	4
554	Usefulness of the angiographic pattern of in-stent restenosis in predicting the success of gamma vascular brachytherapy. American Journal of Cardiology, 2003, 92, 1214-1217.	0.7	4
555	FAME and Coronary Stent Investigations. Journal of the American College of Cardiology, 2011, 57, 115-116.	1.2	4
556	Two-Year Safety and Effectiveness of Sirolimus-Eluting Stents (from a Prospective Registry). American Journal of Cardiology, 2011, 107, 528-534.	0.7	4
557	Ticagrelor reduces thrombus formation more than clopidogrel, even when co-administered with bivalirudin. Thrombosis and Haemostasis, 2014, 112, 1069-1070.	1.8	4
558	Antithrombotic strategy variability in ATrial fibrillation and obstructive coronary disease revascularized with PCIâ€"rationale and study design of the prospective observational multicenter AVIATOR 2 registry. American Heart Journal, 2015, 170, 1234-1242.	1.2	4

#	Article	IF	Citations
559	Cerebrovascular Events After a Primary Percutaneous Coronary Intervention Strategy for Acute ST-Segmentâ€“ Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2015, 8, .	1.4	4
560	Impact of anticoagulation regimen prior to revascularization in patients with nonâ€‹<scp>ST</scp>â€‹segment elevation acute coronary syndromes: The <scp>ACUITY</scp> trial. Catheterization and Cardiovascular Interventions, 2016, 88, 174-181.	0.7	4
561	Effect of valve design and anticoagulation strategy on 30â€‹day clinical outcomes in transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial. Catheterization and Cardiovascular Interventions, 2017, 90, 1016-1026.	0.7	4
562	Relationship Between Stent Diameter, Platelet Reactivity, and Thrombotic Events After Percutaneous Coronary Artery Revascularization. American Journal of Cardiology, 2019, 124, 1363-1371.	0.7	4
563	New-generation drug-eluting stents for left main coronary artery disease according to the EXCEL trial enrollment criteria: Insights from the all-comers, international, multicenter DELTA-2 registry. International Journal of Cardiology, 2019, 280, 30-37.	0.8	4
564	Report of the European Society of Cardiology Cardiovascular Round Table regulatory workshop update of the evaluation of new agents for the treatment of acute coronary syndrome: Executive summary. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 745-754.	0.4	4
565	Safety and efficacy of bivalirudin monotherapy in patients with non-ST-segment elevation acute coronary syndromes with positive biomarkers undergoing percutaneous coronary intervention: a report from the Acute Catheterization and Urgent Intervention Triage Strategy trial. Coronary Artery Disease, 2020, 31, 59-65.	0.3	4
566	Sex differences in 1â€‹year clinical outcomes after percutaneous coronary intervention with COMBO stents: From the COMBO collaboration. Catheterization and Cardiovascular Interventions, 2021, 97, 797-804.	0.7	4
567	Perioperative risk and antiplatelet management in patients undergoing non-cardiac surgery within 1 year of PCI. Journal of Thrombosis and Thrombolysis, 2022, 53, 380-389.	1.0	4
568	Impact of bleeding assessment and adjudication methodology on event rates and clinical trial outcomes: insights from the HORIZONS-AMI trial. EuroIntervention, 2018, 14, e580-e587.	1.4	4
569	Effect of Elevated C-Reactive Protein on Outcomes After Complex Percutaneous Coronary Intervention for Angina Pectoris. American Journal of Cardiology, 2022, 168, 47-54.	0.7	4
570	Device and Procedure Relatedness. JACC: Cardiovascular Interventions, 2022, 15, 783-788.	1.1	4
571	Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS120009495.	1.4	4
572	Gamma radiation for in-stent restenosis: effect of lesion length on angiographic and clinical outcomes. Catheterization and Cardiovascular Interventions, 2004, 61, 354-359.	0.7	3
573	Off-label use of drug-eluting stents: assessing the risk. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 594-595.	3.3	3
574	Clinical Impact of Enhanced Inhibition of P2Y₁₂-Mediated Platelet Aggregation in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Hospital Practice (1995), 2010, 38, 38-43.	0.5	3
575	Letter by Mehran et al Regarding Article, â€œBleeding Academic Research Consortium Consensus Report: The Food and Drug Administration Perspectiveâ€. Circulation, 2012, 125, e460.	1.6	3
576	Postprocedural Anticoagulation for Specific Therapeutic Indications After Revascularization for ST-Segment Elevation Myocardial Infarction (from the Harmonizing Outcomes With Revascularization) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.7	3

#	Article	IF	Citations
577	Impact of Pre-Procedural Cardiopulmonary Instability in Patients With Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (from the Harmonizing Outcomes With) Tj ETQq1 1 0.784314 rgBT /Overlock 2014, 114, 962-967.	0.7	3
578	Impact of an integrated treatment algorithm based on platelet function testing and clinical risk assessment: results of the TRIAGE Patients Undergoing Percutaneous Coronary Interventions To Improve Clinical Outcomes Through Optimal Platelet Inhibition study. Journal of Thrombosis and Thrombolysis, 2016, 42, 186-196.	1.0	3
579	Ticagrelor Monotherapy After CoronaryÂStenting. Journal of the American College of Cardiology, 2019, 74, 2235-2237.	1.2	3
580	Adverse events in patients with high platelet reactivity following successful chronic total occlusion PCI: The Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study. American Heart Journal, 2019, 211, 68-76.	1.2	3
581	1-Year Outcomes with COMBO Stents in Small-Vessel Coronary Disease: Subgroup Analysis From the COMBO Collaboration. Cardiovascular Revascularization Medicine, 2020, 21, 1542-1547.	0.3	3
582	Drug-coated stents versus bare metal stents in Academic Research Consortium-defined high bleeding risk patients. EuroIntervention, 2021, 17, 240-247.	1.4	3
583	Clinical outcomes according to lesion complexity in high bleeding risk patients treated with 1â€•month dual antiplatelet therapy following <scp>PCI</scp>: Analysis from the <scp>Onyx ONE</scp> clear study. Catheterization and Cardiovascular Interventions, 2022, 99, 583-592.	0.7	3
584	Impact of time to treatment on the effects of bivalirudin vs. glycoprotein IIb/IIIa inhibitors and heparin in patients undergoing primary percutaneous coronary intervention: insights from the HORIZONS-AMI trial. EuroIntervention, 2016, 12, 1144-1153.	1.4	3
585	Prevalence and Impact of High Bleeding Risk in Patients Undergoing Left Main Artery Disease PCI. JACC: Cardiovascular Interventions, 2021, 14, 2447-2457.	1.1	3
586	Clinical events classification (CEC) in clinical trials: Report on the current landscape and future directions â€" proceedings from the CEC Summit 2018. American Heart Journal, 2022, 246, 93-104.	1.2	3
587	Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke. JAMA Cardiology, 2022, 7, 682.	3.0	3
588	Favorable effect of ?-radiation for in-stent restenosis: Effect of diabetes on angiographic and clinical outcomes. Catheterization and Cardiovascular Interventions, 2004, 62, 303-307.	0.7	2
589	Comparison of Catheterization Laboratory Initiated Abciximab and Eptifibatide During Percutaneous Coronary Intervention in Acute Coronary Syndromes (an ACUITY Substudy). American Journal of Cardiology, 2010, 106, 180-186.	0.7	2
590	Response to Letter Regarding Article, â€œPrognostic Modeling of Individual Patient Risk and Mortality Impact of Ischemic and Hemorrhagic Complications: Assessment From the Acute Catheterization and Urgent Intervention Triage Strategy Trialâ€• Circulation, 2010, 122, .	1.6	2
591	What is the optimal antithrombotic strategy in primary percutaneous coronary intervention?. Current Opinion in Cardiology, 2012, 27, 361-367.	0.8	2
592	Are adverse events following an invasive strategy in patients with nonâ€ST†segment elevation acute coronary syndromes more frequent at US sites versus Nonâ€US sites? analysis from the ACUITY trial. Catheterization and Cardiovascular Interventions, 2013, 82, E365-74.	0.7	2
593	Drug-eluting stents and drug-eluting balloons are the best strategies to treat coronary in-stent restenosis. Evidence-Based Medicine, 2016, 21, 90-90.	0.6	2
594	Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. Thrombosis and Haemostasis, 2019, 119, 1704-1711.	1.8	2

#	Article	IF	Citations
595	Comparative influence of bleeding and ischemic risk factors on diabetic patients undergoing percutaneous coronary intervention with everolimusâ€eluting stents. Catheterization and Cardiovascular Interventions, 2021, 98, 1111-1119.	0.7	2
596	One-Year COMBO Stent Outcomes in Acute Coronary Syndrome: from the COMBO Collaboration. Cardiovascular Drugs and Therapy, 2021, 35, 309-320.	1.3	2
597	Impact of renal function in high bleeding risk patients undergoing percutaneous coronary intervention: a patient-level stratified analysis from four post-approval studies. Journal of Thrombosis and Thrombolysis, 2021, 52, 419-428.	1.0	2
598	Impact of anemia on shortâ€term outcomes after TAVR : A subgroup analysis from the BRAVO â€3 randomized trial. Catheterization and Cardiovascular Interventions, 2021, 98, E870-E880.	0.7	2
599	Coronary artery bypass graft versus percutaneous coronary intervention with drug-eluting stent implantation for diabetic patients with unprotected left main coronary artery disease: the D-DELTA registry. EuroIntervention, 2013, 9, 803-808.	1.4	2
600	Perioperative Management of P2Y12 Inhibitors in Patients Undergoing Cardiac Surgery within 1 Year of PCI. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, , .	1.4	2
601	Bivalirudin for patients with ST-elevation myocardial infarction â€“ Authors' reply. Lancet, The, 2011, 378, 1915-1916.	6.3	1
602	Bleeding Avoidance in Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2014, 7, 152-153.	1.1	1
603	Classification and patterns of bifurcation in-stent restenosis (BISR) in the second generation drug eluting stent era. Hellenic Journal of Cardiology, 2017, 58, 167-168.	0.4	1
604	Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation. Circulation: Cardiovascular Interventions, 2019, 12, e008160.	1.4	1
605	Comparison of Age (<75 Years Vs â‰¥75 Years) and Platelet Reactivity to the Risk of Thrombotic and Bleeding Events After Successful Percutaneous Coronary Intervention With Drug-Eluting Stents (from the ADAPT-DES Study). American Journal of Cardiology, 2020, 125, 685-693.	0.7	1
606	1-Year COMBO stent outcomes stratified by the PARIS bleeding prediction score: From the MASCOT registry. IJC Heart and Vasculature, 2020, 31, 100605.	0.6	1
607	1-year results after PCI with the COMBO stent in all-comers in Asia versus Europe: Geographical insights from the COMBO collaboration. International Journal of Cardiology, 2020, 307, 17-23.	0.8	1
608	Individualizing dual antiplatelet therapy (DAPT) duration based on bleeding risk, ischemic risk, or both: An analysis from the DAPT Study. Cardiovascular Revascularization Medicine, 2022, , .	0.3	1
609	Evaluating the need for a practical risk score to predict major bleeding in acute coronary syndromes. Interventional Cardiology, 2010, 2, 757-759.	0.0	0
610	Antithrombotics in ACSâ€"moving beyond unfractionated heparin. Nature Reviews Cardiology, 2011, 8, 613-614.	6.1	0
611	Response to Letter Regarding Article, â€œImpact of the Presence and Extent of Incomplete Angiographic Revascularization After Percutaneous Coronary Intervention in Acute Coronary Syndromes: The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) Trialâ€• Circulation, 2012, 126, .	1.6	0
612	Future Perspectives on Percutaneous Coronary Interventions in Women. Interventional Cardiology Clinics, 2012, 1, 251-258.	0.2	0

#	Article	IF	Citations
613	The Use of Bivalirudin in ST-Segment Elevation Myocardial Infarction. Interventional Cardiology Clinics, 2012, 1, 441-451.	0.2	0
614	Balance of Ischemia and Bleeding in Selecting an Antithrombotic Regimen. Interventional Cardiology Clinics, 2013, 2, 515-525.	0.2	0
615	The Optimal Duration of Dual Combination Antiplatelet Therapy After Stent Implantation and Perioperative Management Issues. Interventional Cardiology Clinics, 2013, 2, 585-594.	0.2	0
616	<scp>STEMI</scp> with multivessel disease: An ongoing battle for the optimal treatment strategy. Catheterization and Cardiovascular Interventions, 2016, 88, 707-708.	0.7	0
617	Improving Outcomes in High-Risk Percutaneous Coronary Interventions and Newer-Generation Drug-Eluting Stents: Good, But Not Good Enough. Cardiology, 2017, 138, 73-75.	0.6	0
618	Atrial fibrillation, bleeding, and coronary intervention. Coronary Artery Disease, 2017, 28, 702-709.	0.3	0
619	Oneâ€year clinical outcomes in patients with chronic kidney disease treated with COMBO stents: From the COMBO collaboration. Catheterization and Cardiovascular Interventions, 2020, , .	0.7	0
620	Reducing the cost of managing patients with atrial fibrillation undergoing percutaneous coronary intervention with stenting. Journal of Cardiology, 2021, 77, 93-99.	0.8	0
621	Moving from dual antiplatelet therapy to monotherapy based on P2Y12 receptor blockadeâ€"why it could be a novel paradigm?. , 2021, , 167-191.		0
622	Bivalirudin versus heparin in PCI: Is the pendulum swinging again in favor of heparin?. Catheterization and Cardiovascular Interventions, 2021, 97, 774-775.	0.7	0
623	White blood cell count and clinical outcomes after left main coronary artery revascularization. Coronary Artery Disease, 2021, Publish Ahead of Print, 45-51.	0.3	0
624	Meta-Analysis of Anticoagulation Therapy for the Prevention of Cardiovascular Events in Patients With Peripheral Arterial Disease. American Journal of Cardiology, 2021, 148, 165-171.	0.7	0
625	Interventions in Ischemic Heart Disease. , 2021, , 93-108.		0
626	Drug-Eluting Stents: A Potential Preemptive Treatment Choice for Vulnerable Coronary Plaques. , 2011, , 661-669.		0
627	Bleeding Complications in Patients Undergoing Percutaneous Coronary Intervention. , 2010, , 240-249.		0
628	Interventional Management of Diabetic Coronaropathy and Diffuse Coronary Artery Disease. , 2014, , 1-20.		0
629	Interventional Management of Diabetic Coronaropathy and Diffuse Coronary Artery Disease. , 2015, , 2253-2270.		0
630	Use of Bivalirudin for Anticoagulation in Interventional Cardiovascular Procedures. Cardiovascular Innovations and Applications, 2018, 3, .	0.1	0

#	Article	IF	Citations
631	Potential Clinical Advantages of Drug-Coated Balloon in Specific Clinical Settings. , 2019, , 69-79.		0
632	TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy Versus Ticagrelor Plus Aspirin Beginning at 3 Months in High-risk Patients Undergoing Percutaneous Coronary Intervention. US Cardiology Review, 0, 14, .	0.5	0
633	Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial. Open Heart, 2022, 9, e001892.	0.9	0
634	Efficacy and Safety of Antithrombotic Therapy in Patients With Atrial Fibrillation, Recent Acute Coronary Syndrome, or Percutaneous Coronary Intervention and a History of Heart Failure: Insights From the AUGUSTUS Trial. Journal of the American Heart Association, 2021, 10, e023143.	1.6	0